{"paper_id": "f7a8d166836c9737279a80c96a2d61c8aa51a44e", "metadata": {"title": "Screening for natural and derived bio-active compounds in preclinical and clinical studies: one of the frontlines of fighting the coronaviruses pandemic", "authors": [{"first": "Shaden", "middle": ["A M"], "last": "Khalifa", "suffix": "", "affiliation": {"laboratory": "", "institution": "Stockholm University", "location": {"addrLine": "S-106 91", "settlement": "Stockholm", "country": "Sweden"}}, "email": ""}, {"first": "Nermeen", "middle": [], "last": "Yosri", "suffix": "", "affiliation": {"laboratory": "", "institution": "Menoufia University", "location": {"addrLine": "32512 Shebin El-Kom", "country": "Egypt"}}, "email": ""}, {"first": "Mohamed", "middle": ["F"], "last": "El-Mallah", "suffix": "", "affiliation": {"laboratory": "", "institution": "Menoufia University", "location": {"addrLine": "32512 Shebin El-Kom", "country": "Egypt"}}, "email": ""}, {"first": "Reem", "middle": [], "last": "Ghonaimb", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhiming", "middle": [], "last": "Guo", "suffix": "", "affiliation": {"laboratory": "", "institution": "Jiangsu University", "location": {"postCode": "212013", "settlement": "Zhenjiang", "country": "China"}}, "email": ""}, {"first": "Ghulam", "middle": [], "last": "Syed", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Ming", "middle": [], "last": "Musharraf", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Alfi", "middle": [], "last": "Du", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jianbo", "middle": [], "last": "Khatib", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Aamer", "middle": [], "last": "Xiao", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Haged", "middle": ["H R"], "last": "Saeed", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Chao", "middle": [], "last": "El-Seedi", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Thomas", "middle": [], "last": "Zhao", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Hesham", "middle": ["R"], "last": "Efferth", "suffix": "", "affiliation": {}, "email": ""}, {"first": "", "middle": [], "last": "El-Seedi", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Reem", "middle": [], "last": "Ghonaim", "suffix": "", "affiliation": {"laboratory": "", "institution": "Menoufia University", "location": {"addrLine": "32512 Shebin El-Kom", "country": "Egypt"}}, "email": ""}, {"first": "Syed", "middle": [], "last": "Ghulam Musharraf", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Karachi", "location": {"settlement": "Karachi-75270", "country": "Pakistan"}}, "email": ""}, {"first": "Ming", "middle": [], "last": "Du", "suffix": "", "affiliation": {"laboratory": "", "institution": "Dalian Polytechnic University", "location": {"postCode": "116024", "settlement": "Dalian", "country": "China"}}, "email": ""}, {"first": "Alfi", "middle": [], "last": "Khatib", "suffix": "", "affiliation": {"laboratory": "", "institution": "International Islamic University Malaysia", "location": {"postCode": "25200", "settlement": "Kuantan, Pahang", "country": "Malaysia"}}, "email": ""}, {"first": "Jianbo", "middle": [], "last": "Xiao", "suffix": "", "affiliation": {"laboratory": "State Key Laboratory of Quality Control in Chinese Medicine", "institution": "University of Macau", "location": {"settlement": "Macau"}}, "email": ""}, {"first": "Aamer", "middle": [], "last": "Saeed", "suffix": "", "affiliation": {"laboratory": "", "institution": "Quaid-i-Azam University", "location": {"settlement": "Islamabad", "country": "Pakistan"}}, "email": ""}, {"first": "Haged", "middle": ["H R"], "last": "El-Seedi", "suffix": "", "affiliation": {"laboratory": "", "institution": "Karolinska Institutet", "location": {"postCode": "171 77", "settlement": "Solna", "country": "Sweden"}}, "email": ""}, {"first": "Chao", "middle": [], "last": "Zhao", "suffix": "", "affiliation": {"laboratory": "", "institution": "Fujian Agriculture and Forestry University", "location": {"postCode": "350002", "settlement": "Fuzhou", "country": "China"}}, "email": ""}, {"first": "Thomas", "middle": [], "last": "Efferth", "suffix": "", "affiliation": {"laboratory": "", "institution": "Johannes Gutenberg University", "location": {"addrLine": "Staudinger Weg 5", "postCode": "55128", "settlement": "Mainz", "country": "Germany"}}, "email": ""}, {"first": "Hesham", "middle": ["R"], "last": "El-Seedi", "suffix": "", "affiliation": {"laboratory": "", "institution": "Stockholm University", "location": {"addrLine": "S-106 91", "settlement": "Stockholm", "country": "Sweden"}}, "email": ""}]}, "abstract": [{"text": "publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Journal Pre-proof Screening for natural and derived bio-active compounds in preclinical and clinical studies: one of the frontlines of fighting the coronaviruses pandemic Screening for natural and derived bio-active compounds in preclinical and clinical studies: one of the frontlines of fighting the coronaviruses pandemic, Phytomedicine (2020), doi: https://doi.Abstract Background: Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods: A literature search was performed for the screening of natural and derived bioactive compounds which showed potent antiviral activity against coronaviruses using published articles, patents, clinical trials website (https://clinicaltrials.gov/) and web databases (PubMed, SCI Finder, Science Direct, and Google Scholar). Results: Through the screening for natural products with antiviral activities against seven types of the human coronavirus, extracts of Lycoris radiata, Gentiana scabra, Dioscorea batatas, Cassia tora, Taxillus chinensis Cibotium barometz and Echinacea purpurea showed a promising effect against SARS-COV. Out of the listed compound Lycorine, emetine dihydrochloride hydrate, pristimerin, harmine, conessine, berbamine, 4`-hydroxychalcone, papaverine, mycophenolic acid, mycophenolate mofetil, monensin sodium, cycloheximide, oligomycin and valinomycin show potent activity against human coronaviruses. Additionally, it is worth noting that some compounds have already moved into clinical trials for their activity against COVID-19 including fingolimod, methylprednisolone, chloroquine, tetrandrine and tocilizumab. Conclusion: Natural compounds and their derivatives could be used for developing potent therapeutics with significant activity against SARS-COV-2, providing a promising frontline in the fighting against COVID-19.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "Coronaviruses were isolated in 1965 from the respiratory tract of adult humans with common cold symptoms (Kahn and McIntosh, 2005) . At the beginning, the endemic corona viruses such as: HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 caused mild upper respiratory disease in humans (Chan and Chan, 2013) . In the past two decades coronaviruses have appeared on a large pandemic scale displayed by the appearance of the severe acute respiratory syndrome virus (SARS-CoV) followed by the other types of Coronaviruses (MERS-CoV) (Chan-Yeung and Xu, 2003) . The severe respiratory syndrome virus reached many countries and affected many people after crossover from animal (bats as a natural reservoir host) to human, causing high fatality rates (Yuan et al., 2017) . The novel SARS-CoV-2 belongs to the coronavirus family that appears to have originated from bats with unknown intermediate host (s) .", "cite_spans": [{"start": 105, "end": 130, "text": "(Kahn and McIntosh, 2005)", "ref_id": "BIBREF37"}, {"start": 282, "end": 303, "text": "(Chan and Chan, 2013)", "ref_id": null}, {"start": 526, "end": 551, "text": "(Chan-Yeung and Xu, 2003)", "ref_id": null}, {"start": 741, "end": 760, "text": "(Yuan et al., 2017)", "ref_id": "BIBREF114"}], "ref_spans": [], "section": "Introduction"}, {"text": "Nowadays, the incidence and spread of the new coronavirus disease 2019 in Wuhan City, Hubei province in China became a threat to the world and a recent public health crisis (Singhal, 2020) . On the 11 th of February 2020 the International Committee on Taxonomy of Viruses called it the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Chhikara et al., 2020) . The primary causative factor of infection transmission is the direct contact with patients such as: handshakes, contaminated surfaces and indirect inhalation of infected respiratory droplets, hence the incubation period which should be enforced around 14 days (Chhikara et al., 2020; Sohrabi et al., 2020) .", "cite_spans": [{"start": 173, "end": 188, "text": "(Singhal, 2020)", "ref_id": "BIBREF78"}, {"start": 347, "end": 370, "text": "(Chhikara et al., 2020)", "ref_id": null}, {"start": 633, "end": 656, "text": "(Chhikara et al., 2020;", "ref_id": null}, {"start": 657, "end": 678, "text": "Sohrabi et al., 2020)", "ref_id": "BIBREF80"}], "ref_spans": [], "section": "Introduction"}, {"text": "The usual clinical signs are manifested as: dry cough, fever, headache, pneumonia, and breathing difficulties (dyspnea). Subsequently, the respiratory infection causes alveolar damage and respiratory failure, additionally, a decrease in the number of white", "cite_spans": [], "ref_spans": [], "section": "Introduction"}, {"text": "Human coronaviruses (CoVs) are enveloped viruses, classified into seven types namely HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) ( Fig. 1) (Corman et al., 2018; Pillaiyar et al., 2020) .", "cite_spans": [{"start": 184, "end": 205, "text": "(Corman et al., 2018;", "ref_id": "BIBREF6"}, {"start": 206, "end": 229, "text": "Pillaiyar et al., 2020)", "ref_id": "BIBREF66"}], "ref_spans": [{"start": 176, "end": 183, "text": "Fig. 1)", "ref_id": null}], "section": "1. Coronaviruses types and classifications"}, {"text": "The first two CoVs were reported in 1960's, followed by the discovery of four other types in the 1970's (Lau et al., 2006) . The first four have been accompanied by symptoms such as the common cold, cough, fever, nasal congestion, sore throat, sneezing, and neurological diseases (Walsh et al., 2013; Woo et al., 2005) . Their distribution was related mainly to temperate climates during the winter and spring months but geographically they have been observed all over the world (Talbot et al., 2009) . HCoV-229E entered cells via binding to the aminopeptidase N receptor (CD13) found on the surface (Yeager et al., 1992) . The incubation period ranged between 2-5 days (Lessler et al., 2009) . The HCoV-229E virus replicated in the epithelial cell line of the trachea (Shirato et al., 2017) . The First isolation for the HCoV-NL63 type was observed in a 7-month-old baby in early 2004 (Fielding, 2011) . Different clinical evidences were reported and showed that HCoV-NL63 induced similar symptoms to those associated with HCoV-229E and HCoV-OC43 (Talbot et al., 2009) . Since HCoV-NL63 and HCoV-229E can share 65% of their amino acid identity, they have an identical mechanism of cellular entry (van der Hoek et al., 2004) .", "cite_spans": [{"start": 104, "end": 122, "text": "(Lau et al., 2006)", "ref_id": null}, {"start": 280, "end": 300, "text": "(Walsh et al., 2013;", "ref_id": "BIBREF89"}, {"start": 301, "end": 318, "text": "Woo et al., 2005)", "ref_id": "BIBREF96"}, {"start": 479, "end": 500, "text": "(Talbot et al., 2009)", "ref_id": "BIBREF84"}, {"start": 600, "end": 621, "text": "(Yeager et al., 1992)", "ref_id": "BIBREF112"}, {"start": 670, "end": 692, "text": "(Lessler et al., 2009)", "ref_id": "BIBREF40"}, {"start": 769, "end": 791, "text": "(Shirato et al., 2017)", "ref_id": "BIBREF76"}, {"start": 886, "end": 902, "text": "(Fielding, 2011)", "ref_id": null}, {"start": 1048, "end": 1069, "text": "(Talbot et al., 2009)", "ref_id": "BIBREF84"}, {"start": 1197, "end": 1224, "text": "(van der Hoek et al., 2004)", "ref_id": "BIBREF86"}], "ref_spans": [], "section": "1. Coronaviruses types and classifications"}, {"text": "Severe Acute Respiratory Syndrome Coronavirus (SARS CoV) disproportionately infected adults, with notable severe symptoms i.e. fever, chills, myalgia, malaise, and headache, followed by a non-productive cough and dyspnea 3-5 days later (Fowler et al., 2003; Tsui et al., 2003) . SARS-CoV was also named atypical pneumonia and was recorded as the first pandemic virus in human history (Peiris et al., 2003) . Its incubation period is 2-10 days (World Health Organization, 2003) . Young children and infants infected with SARS-CoV suffered from less severe symptoms than youth and adults (Bitnun et al., 2003) . Infection with SARS-CoV type started by the inoculation of respiratory tract mucosa through Angiotensin-converting enzyme 2 (Li et al., 2003) .", "cite_spans": [{"start": 236, "end": 257, "text": "(Fowler et al., 2003;", "ref_id": null}, {"start": 258, "end": 276, "text": "Tsui et al., 2003)", "ref_id": "BIBREF86"}, {"start": 384, "end": 405, "text": "(Peiris et al., 2003)", "ref_id": "BIBREF65"}, {"start": 443, "end": 476, "text": "(World Health Organization, 2003)", "ref_id": null}, {"start": 586, "end": 607, "text": "(Bitnun et al., 2003)", "ref_id": null}, {"start": 734, "end": 751, "text": "(Li et al., 2003)", "ref_id": "BIBREF45"}], "ref_spans": [], "section": "1. Coronaviruses types and classifications"}, {"text": "Middle East Respiratory Syndrome Coronavirus (MERS-CoV) rarely infected children, but it can cause severe infections for youth. Infected cases with MERS-CoV suffered from many symptoms i.e. fever, cough, chills, sore throat, myalgia, arthralgia, dyspnea, pneumonia, diarrhea and vomiting (Assiri et al., 2013) . It was isolated for the first time in a Saudi Arabian patient in 2012, then in another case from South Korea in 2015. About 2500 fatality cases were reported in February 2020 (Gao et al., 2016; Hilgenfeld and Peiris, 2013; Ye et al., 2020) . Its incubation period ranged from 2-13 days (Coleman and Frieman, 2013) . MERS-CoV infection started with inoculation of the respiratory tract mucosa mediated by functional receptors such as dipeptidyl peptidase 4 (DPP4) (Ng et al., 2016) . Then the world faced a new challenge in December 2019, starting with the recording of the first SARS-CoV-2 case in Wuhan, Hubei province, China . The statistics reported on the of 14 th July 2020, confirmed that the number of fatality cases reached 570288 total cases worldwide (World Health Organization, 2020a).", "cite_spans": [{"start": 288, "end": 309, "text": "(Assiri et al., 2013)", "ref_id": null}, {"start": 487, "end": 505, "text": "(Gao et al., 2016;", "ref_id": "BIBREF14"}, {"start": 506, "end": 534, "text": "Hilgenfeld and Peiris, 2013;", "ref_id": "BIBREF24"}, {"start": 535, "end": 551, "text": "Ye et al., 2020)", "ref_id": "BIBREF111"}, {"start": 598, "end": 625, "text": "(Coleman and Frieman, 2013)", "ref_id": "BIBREF5"}, {"start": 775, "end": 792, "text": "(Ng et al., 2016)", "ref_id": null}], "ref_spans": [], "section": "1. Coronaviruses types and classifications"}, {"text": "SARS-CoV-2 causes severe respiratory infection accompanied by different symptoms i.e. fever, cough, dyspnea, myalgia, and headache . SARS-CoV-2 is mostly less pathogenic, but spreads more compared to SARS-CoV and MERS-CoV (Zhou et al., 2020).", "cite_spans": [], "ref_spans": [], "section": "1. Coronaviruses types and classifications"}, {"text": "In Wuhan, the capital of central China's Hubei province, the Coronavirus (COVID-", "cite_spans": [], "ref_spans": [], "section": "SARS-CoV-2 Origin, Taxonomy and Structure"}, {"text": "System recorded the first case on December 8, (Bai et al., 2020 Wu and McGoogan, 2020) . The city's Huanan Seafood Market was the origin of the zoonotic virus SARS-CoV-2 which was transferred rapidly (Chan et al., 2020) . The recent phylogenetic analysis detected that SARS-CoV-2 may be evolved from a strain found in bats, thus considered the natural reservoir host of SARS-CoV-2 (H. . Till now, the researchers are not sure about the intermediate host(s) of SARS-CoV-2 or whether the infection can be transmitted directly from bat to human . It was then recognized as worldwide pandemic disease that can be transmitted rapidly between humans through droplets or direct contact (Z. .", "cite_spans": [{"start": 46, "end": 63, "text": "(Bai et al., 2020", "ref_id": "BIBREF11"}, {"start": 64, "end": 86, "text": "Wu and McGoogan, 2020)", "ref_id": "BIBREF102"}, {"start": 200, "end": 219, "text": "(Chan et al., 2020)", "ref_id": "BIBREF111"}], "ref_spans": [], "section": "19) outbreak appeared at the end of 2019, where China's Infectious Disease Information"}, {"text": "2019-nCoV (COVID-19; also named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel member of the coronaviruses .", "cite_spans": [], "ref_spans": [], "section": "19) outbreak appeared at the end of 2019, where China's Infectious Disease Information"}, {"text": "Nevertheless, it has a specific gene sequence that differentiates it from previously sequenced coronaviruses . Interestingly, it has an 88% shared identity with SARS-CoV and about 50% to MERS-CoV, indicating that it belongs to the same species (H. Lu et al., 2020) . The phylogenetic analysis done to classify SARS-CoV-2 revealed that it falls into the Sarbecovirus subgenus of the genus Betacoronavirus Zhu et al., 2020) .", "cite_spans": [{"start": 248, "end": 264, "text": "Lu et al., 2020)", "ref_id": "BIBREF57"}, {"start": 404, "end": 421, "text": "Zhu et al., 2020)", "ref_id": "BIBREF57"}], "ref_spans": [], "section": "19) outbreak appeared at the end of 2019, where China's Infectious Disease Information"}, {"text": "In general, HCoVs are long and positive single stranded RNA viruses characteristic of two groups of proteins; the first group is namely the structural proteins: Spike (S), Nucleocapsid (N), Matrix (M), and Envelope (E) (Fig. 2) , while the second group is nonstructural proteins: proteases (nsp3 and nsp5) and RdRp (nsp12) (Elfiky et al., 2017) . In the case of SARS-CoV-2, the densely glycosylated spike protein found on the outer surface is arranged in this way in order to facilitate the recognition, attachment, and entry into the host cell (Ibrahim et al., 2020) . Similarly, the genetic material of SARS-CoV-2 is a positive sense RNA strand (Chhikara et al., 2020) . SARS-CoV-2 was described with a transmission electron microscope (TEM) where the double-wall surface of SARS-CoV-2 was seen, but it gives only a poor description of the different organelles in the cytoplasm (Chhikara et al., 2020; Walls et al., 2020) . Thus, it was assumed that SARS-CoV-2 has distinct ultrastructural features similar to the coronavirus family such double-membrane vesicles, large granular areas of cytoplasm and nucleocapsid inclusions, in addition to viral proteins and genetic material RNA (Chhikara et al., 2020). are similar in the mechanism of replication (He et al., 2020) . Its replication begins with the binding of its spike protein (S) into the host's cell surface molecules (Sahin et al., 2020) . Usually, (S) protein is divided functionally into the S1 domain, responsible for binding to human receptors, and the S2 domain is responsible for cell membrane fusion (He et al., 2004) . SARS-CoV-2 enters the host cells through recognition of human receptor angiotensin-converting enzyme 2 (ACE2) . RNA material of SARS-CoV-2 undergoes replication and transcription after the fusion with the plasma membrane. Replicase proteins of SARS-CoV-2 are generated from translation of positive sense RNA genomes through open reading frame 1a/b (ORF1a/b). These proteins use positive sense RNA as a template to generate full-length negative sense RNA. Then proteins are collected with new RNA genome assembly in the endoplasmic reticulum (ER) and Golgi-apparatus ( Fig. 3) (He et al., 2020) . Biophysical and structural analysis confirmed that the S protein of SARS-CoV-2 has an affinity to bind with ACE2 about 10-20 times higher than the S protein of SARS-CoV (Wrapp et al., 2020) . The high affinity of the S protein for human ACE2 can facilitate the spread of SARS-CoV-2 between humans .", "cite_spans": [{"start": 323, "end": 344, "text": "(Elfiky et al., 2017)", "ref_id": null}, {"start": 545, "end": 567, "text": "(Ibrahim et al., 2020)", "ref_id": "BIBREF26"}, {"start": 647, "end": 670, "text": "(Chhikara et al., 2020)", "ref_id": null}, {"start": 880, "end": 903, "text": "(Chhikara et al., 2020;", "ref_id": null}, {"start": 904, "end": 923, "text": "Walls et al., 2020)", "ref_id": "BIBREF88"}, {"start": 1253, "end": 1270, "text": "(He et al., 2020)", "ref_id": "BIBREF22"}, {"start": 1377, "end": 1397, "text": "(Sahin et al., 2020)", "ref_id": "BIBREF73"}, {"start": 1567, "end": 1584, "text": "(He et al., 2004)", "ref_id": "BIBREF23"}, {"start": 2163, "end": 2180, "text": "(He et al., 2020)", "ref_id": "BIBREF22"}, {"start": 2352, "end": 2372, "text": "(Wrapp et al., 2020)", "ref_id": null}], "ref_spans": [{"start": 219, "end": 227, "text": "(Fig. 2)", "ref_id": null}, {"start": 2155, "end": 2162, "text": "Fig. 3)", "ref_id": null}], "section": "19) outbreak appeared at the end of 2019, where China's Infectious Disease Information"}, {"text": "The studies conducted on the COVID-19 infection mechanism showed an increase in leukocyte levels, plasma pro-inflammatory cytokines i.e. IL-6, and blood C-reactive protein values from the normal range . Lower numbers of T and B lymphocytes in peripheral blood are observed and coagulation parameters i.e. D-Dimer raise abnormally . The main pathogenesis of the COVID-19 infection is described as extreme pneumonia, RNAaemia, and acute cardiac injury . The high rate of renal failure was observed in patients with COVID-19, suggesting the development of renal dysfunction (Q. .", "cite_spans": [], "ref_spans": [], "section": "SARS"}, {"text": "The human-to-human spread is now the primary way of transmission of the infection; from both symptomatic and asymptomatic individuals. The transmission from symptomatic patients occurs to nearby individuals but does not occur through air.", "cite_spans": [], "ref_spans": [], "section": "SARS"}, {"text": "Transmission from asymptomatic individuals occurs through direct contact, handshaking (Kam et al., 2020) , touching contaminated surfaces (Bai et al., 2020) or droplets spread by coughing or sneezing then touching the mouth, nose or eyes (Pan et al., 2020) . Therefore, the human-to-human transmission depends on proximity and increased population density. Also, Leung et al., 2020 proved that inadequate use of masks could lead to increased chances of infection transmission On the other hand, SARS-CoV-2 has infected roughly 7690708 individuals in more than 200 countries until the 14 th of June 2020 (World Health Organization, 2020b). Meaning that the transmission of SARS-CoV-2 is higher than SARS-CoV. Li et al., 2020 proved that the high spread of COVID-19 is due to the genetic recombinant S protein (Q. . Initial reports identified two species of snakes that may be a reservoir of SARS-CoV-2 (Ji et al., 2020; Rothan and Byrareddy, 2020) . Mammals or birds are the only evidenced reservoirs of SARS-CoV-2 (Bassetti et al., 2020). Genomic sequence analysis of SARS-CoV-2 showed an 88% identity share with two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses (Chan et al., 2020; Lu et al., 2020; . Despite the fact that the genetic material of SARS-CoV-2 is compatible with other types of coronavirus, its gene sequences remarkably differ from previous sequences of other CoV types (Zhou et al., 2020) . The genetic studies of SARS-CoV-2 showed that its sequence shared 79% identity with the other CoVs types .", "cite_spans": [{"start": 86, "end": 104, "text": "(Kam et al., 2020)", "ref_id": "BIBREF39"}, {"start": 138, "end": 156, "text": "(Bai et al., 2020)", "ref_id": "BIBREF11"}, {"start": 238, "end": 256, "text": "(Pan et al., 2020)", "ref_id": "BIBREF62"}, {"start": 363, "end": 381, "text": "Leung et al., 2020", "ref_id": "BIBREF41"}, {"start": 708, "end": 730, "text": "Li et al., 2020 proved", "ref_id": null}, {"start": 901, "end": 918, "text": "(Ji et al., 2020;", "ref_id": "BIBREF34"}, {"start": 919, "end": 946, "text": "Rothan and Byrareddy, 2020)", "ref_id": "BIBREF71"}, {"start": 1189, "end": 1208, "text": "(Chan et al., 2020;", "ref_id": "BIBREF111"}, {"start": 1209, "end": 1225, "text": "Lu et al., 2020;", "ref_id": "BIBREF57"}, {"start": 1402, "end": 1431, "text": "CoV types (Zhou et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "SARS"}, {"text": "Despite huge efforts, the world has been unable to discover potential therapies or vaccines against COVID-19, thus most of the scientific efforts are now allocated towards trying to locate a proper medication from the old conventional drugs applied earlier for previous coronavirus varieties, among them are HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 which caused mild upper respiratory disease in humans, as well as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV (Pillaiyar et al., 2020) . Natural products, mainly plants, remain as a rich source of novel therapeutic agents for the treatment of different human illnesses (Yang et al., 2020) . In this context, many natural product derivative therapeutic agents have been Glycyrrhizin (34) is an active terpenoid saponin compound isolated from liquorice roots (Glycyrrhiza glabra L.). Liquorice roots have been used in traditional medicine as prophylactic agent for gastric and duodenal ulcers, anti-inflammatory, contraceptive, laxative, anti-asthmatic, galactagogue, and antiviral, and expectorant (Damle, 2014; Sato et al., 1996) . Cinatl et al. demonstrated that glycyrrhizin inhibited SARS virus replication by inhibition of adsorption. The penetration of the virus at early steps of the replicative cycle was stopped at both concentrations of (EC 50 of 300 mg/L) and CC 50 value of >20 000 mg/L in comparison to ribavirin (positive control) when greater than >1000 that could not be tolerated by the target tissue or organs (Cinatl et al., 2003) . Toona sinensis Roem, is a Chinese traditional plant belonging to the Meliaceae family. In folk medicine, the leaves of the plant were used to treat gastric ulcers, enteritis, dysentery, cerebrovascular, and cardiovascular diseases (Kakumu et al., 2014) . TSL-1, a fraction of the aqueous extract of the plant leaves showed anti-viral activity against SARS-coronavirus with EC 50 of 30 \u00b5g/mL and CC 50 value >500 \u00b5g/mL via inhibition of the viral replication. Determination of CC 50 takes place by decreasing the cell viability by 50% (Chen et al., 2008) . Another study was conducted by Wen et al., where 200 plants were tested and only five of them, namely Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis, exerted survival inhibition of SARS-CoV (Wen et al., 2011) .", "cite_spans": [{"start": 514, "end": 538, "text": "(Pillaiyar et al., 2020)", "ref_id": "BIBREF66"}, {"start": 673, "end": 692, "text": "(Yang et al., 2020)", "ref_id": "BIBREF119"}, {"start": 1101, "end": 1114, "text": "(Damle, 2014;", "ref_id": "BIBREF9"}, {"start": 1115, "end": 1133, "text": "Sato et al., 1996)", "ref_id": "BIBREF74"}, {"start": 1531, "end": 1552, "text": "(Cinatl et al., 2003)", "ref_id": "BIBREF4"}, {"start": 1786, "end": 1807, "text": "(Kakumu et al., 2014)", "ref_id": "BIBREF38"}, {"start": 2089, "end": 2108, "text": "(Chen et al., 2008)", "ref_id": null}, {"start": 2142, "end": 2153, "text": "Wen et al.,", "ref_id": null}, {"start": 2154, "end": 2170, "text": "where 200 plants", "ref_id": null}, {"start": 2326, "end": 2344, "text": "(Wen et al., 2011)", "ref_id": "BIBREF95"}], "ref_spans": [], "section": "1. Drugs management in preclinical studies (in vivo, in vitro)"}, {"text": "The plants possess a wide range of folk applications including liver disorder, inflammation and pneumonia treatment Oh et al., 2004; Pawar and D'mello, 2011; Zhang et al., 2013) . The potent inhibition of SARS-CoV viral enzymatic activity (SARS-CoV 3CL protease) occurred between 25-200 \u00b5g/ml and the most potent plants were C. barometz and D. batatas with IC 50 value of 39 and 44 \u00b5g/ml respectively.", "cite_spans": [{"start": 116, "end": 132, "text": "Oh et al., 2004;", "ref_id": null}, {"start": 133, "end": 157, "text": "Pawar and D'mello, 2011;", "ref_id": "BIBREF64"}, {"start": 158, "end": 177, "text": "Zhang et al., 2013)", "ref_id": null}], "ref_spans": [], "section": "1. Drugs management in preclinical studies (in vivo, in vitro)"}, {"text": "The six plant extracts recorded the same CC 50 value of >500 \u00b5g/ml in comparison with valinomycin (positive control) that has value of 75.01 \u00b5g/mL. The determination of CC 50", "cite_spans": [], "ref_spans": [], "section": "1. Drugs management in preclinical studies (in vivo, in vitro)"}, {"text": "showed that reduction of cell viability by 50% and there was no effect on the growth of host cells, indicating the effectiveness and safety of these extracts (Wen et al., 2011) . Marines natural products, i.e. halitunal (69), mycalamide (70) and esculetin-4carboxylic acid ethyl ester (68) showed antiviral activity against coronaviruses. Halitunal is a diterpene aldehyde isolated from the marine alga Halimeda tuna, known to exert an impact against murine coronavirus strain A59 at a dose of 20 \u00b5g by reduction of cell fusion (Koehn et al., 1991) . Mycalamide is an alkaloid compound isolated from the Mycale sp. sponge that inhibited the MHV-A59 coronavirus replication by blocking the protein synthesis (Donia and Hamann, 2003) . Additionally, esculetin-4-carboxylic acid ethyl ester, is a coumarin compound derived from the Axinella cf. corrugate sponge that down-regulates the SARS 3CL-protease (Lira et al., 2007) . Streptomyces cinnamonensi actinobacteria culture containing glucose, soybean oil, and grit (\u0141owicki and Huczy\u0144ski, 2013) . Monensin sodium exhibited antiviral activity against diverse coronaviruses (EC 50 = 0.18-3.81 \u00b5M) (Shen et al., 2019) . Formerly, monensin and monensin sodium inhibited avian infectious bronchitis virus replication by blocking glycoprotein transport to plasma membranes at the level of the Golgi complex (Alonso-Caplen et al., 1984; Niemann et al., 1982) . Cycloheximide, oligomycins, valinomycin and antimycin A were used against a wide spectrum of Coronaviruses by inhibiting protein synthesis and viral replication with EC 50 of (0.43-5.21), (0.19 -6.43), (1.89-6.78) and (1.65-6.89), respectively. As well these compounds recorded CC 50 value range between (2.96-3.24), (4.26-6.78), (4.12-6.15) and (3.62-4.32) respectively (Shen et al., 2019) .", "cite_spans": [{"start": 158, "end": 176, "text": "(Wen et al., 2011)", "ref_id": "BIBREF95"}, {"start": 528, "end": 548, "text": "(Koehn et al., 1991)", "ref_id": null}, {"start": 707, "end": 731, "text": "(Donia and Hamann, 2003)", "ref_id": null}, {"start": 901, "end": 920, "text": "(Lira et al., 2007)", "ref_id": null}, {"start": 1014, "end": 1043, "text": "(\u0141owicki and Huczy\u0144ski, 2013)", "ref_id": "BIBREF56"}, {"start": 1144, "end": 1163, "text": "(Shen et al., 2019)", "ref_id": "BIBREF75"}, {"start": 1350, "end": 1378, "text": "(Alonso-Caplen et al., 1984;", "ref_id": "BIBREF0"}, {"start": 1379, "end": 1400, "text": "Niemann et al., 1982)", "ref_id": null}, {"start": 1774, "end": 1793, "text": "(Shen et al., 2019)", "ref_id": "BIBREF75"}], "ref_spans": [], "section": "1. Drugs management in preclinical studies (in vivo, in vitro)"}, {"text": "Mycophenolic acid (MPA) (75) was first isolated from Penicillium spp. fungi by Bartolomeo Gosio in 1893 and was reported to have an immunosuppressive activity against psoriasis (Sollinger, 2004) . Recently, mycophenolic acid was investigated against different types of coronavirus using a high-throughput screening approach, where the MPA showed potent anti-MHV-A59 activity in vitro at an EC 50 value of 0.17 \u00b5M compared to of HCoV-OC43, HCoV-NL63 and MERS-CoV (EC 50 values ranging from 0.18 to 1.95 \u00b5M). The value of CC 50 of MHV-A59 equals 4.18 \u00b5M that is greater than the values of HCoV-OC43, HCoV-NL63 and MERS-CoV ranging from 3.21 to 3.55 \u00b5M (Shen et al., 2019) . Another promising MPA derivative called mycophenolate mofetil (74) was reported to be an immunosuppressant, antineoplastic, and antiviral agent against HCoV-OC43, HCoV-NL63, MERS-CoV and SARS-CoV at EC 50 of 1.58, 0.23, 1.54 and 0.27 \u00b5M. The CC 50 of this compound ranged from 3.01 to 3.43 \u00b5M. The two compounds have similar chemical structures, but MPA showed a higher activity against MHV-A59 (EC 50 = 0.17 \u00b5M) (Shen et al., 2019) . Nowadays, there are 80 running and pending clinical trials in China in a serious attempt to find a potential treatment for COVID-19 (Maxmen, 2020) . In 2020, several compounds isolated from natural products (Figure 7 ; Table 3 ) were tested against coronavirus (COVID-19), i.e. Xiyanping (Mix of 78 and 79). Xiyanping, is a semisynthetic product derived from the active components of the Andrographis paniculata plant, and licensed in China as an anti-inflammatory agent (Chong et al., 2013; Xiao et al., 2013) . Xiyanping injection was investigated on 426 patients diagnosed with moderate to severe SARS-CoV-2 infection, every patient was injected with 10-20 ml of Xiyanping at 500 mg per 20 mL daily plus lopinavir/ritonavir tablets and \u03b1-interferon nebulization.", "cite_spans": [{"start": 177, "end": 194, "text": "(Sollinger, 2004)", "ref_id": "BIBREF81"}, {"start": 650, "end": 669, "text": "(Shen et al., 2019)", "ref_id": "BIBREF75"}, {"start": 1085, "end": 1104, "text": "(Shen et al., 2019)", "ref_id": "BIBREF75"}, {"start": 1239, "end": 1253, "text": "(Maxmen, 2020)", "ref_id": "BIBREF59"}, {"start": 1578, "end": 1598, "text": "(Chong et al., 2013;", "ref_id": "BIBREF3"}, {"start": 1599, "end": 1617, "text": "Xiao et al., 2013)", "ref_id": "BIBREF105"}], "ref_spans": [{"start": 1314, "end": 1323, "text": "(Figure 7", "ref_id": null}, {"start": 1326, "end": 1333, "text": "Table 3", "ref_id": "TABREF5"}], "section": "Celastrus orbiculatus"}, {"text": "The stated drug (lopinavir/ritonavir) has the ability to inhibit protease and CYP3A metabolism thus showing antiviral properties (Driggin et al., 2020) (ClinicalTrials.gov;", "cite_spans": [], "ref_spans": [], "section": "2. Curative efficacy of clinical studies and approved drugs"}, {"text": "Fingolimod (FTY720) (80), another compound derived from myriocin (ISP-1), is a metabolite of the Isaria sinclairii fungus. Fingolimod has been approved by the regulatory authorities of the US, EU, Australia, and Russia, to treat the relapsing remitting multiple sclerosis. Fingolimod consequently represents the primary oral drug for treatment of this central nervous autoimmune disease (Ingwersen et al., 2012) . In China, the Fingolimod drug was tested with 30 patients infected with COVID-19. Every patient was given 0.5 mg of Fingolimod orally daily, for three consecutive days. Commission for the treatment of inflammation in patients with COVID-19 (Cron and Chatham, 2020) . Previously, Tocilizumab (Actemra \u00ae ) was permitted by means of the FDA as a drug used for inflammatory bowel disease treatment (Newman and Cragg, 2020). Recently, some physicians in Italy (Pascale Hospital, Naples) claimed that Actemra \u00ae (Tocilizumab) succeeded in treating severely ill patients via blocking the inflammatory molecule interleukin-6, decreasing systemic inflammation, improving survival rate, adjusting hemodynamic and relieving the respiratory distress (Day, 2020) .", "cite_spans": [{"start": 387, "end": 411, "text": "(Ingwersen et al., 2012)", "ref_id": "BIBREF29"}, {"start": 654, "end": 678, "text": "(Cron and Chatham, 2020)", "ref_id": "BIBREF8"}, {"start": 1151, "end": 1162, "text": "(Day, 2020)", "ref_id": "BIBREF10"}], "ref_spans": [], "section": "NCT04275388)"}, {"text": "Severe Acute Respiratory Syndrome (SARS) and Severe Acute Respiratory Distress Syndrome (ARDS), the first one is an enzyme isolated from the Streptococci bacteria and the other is a glycosaminoglycan derived from dog liver (Anderson et al., 1948; McLean, 1959 ). The two compounds had been administrated in 40 patients infected with ARDS.", "cite_spans": [{"start": 223, "end": 246, "text": "(Anderson et al., 1948;", "ref_id": "BIBREF1"}, {"start": 247, "end": 259, "text": "McLean, 1959", "ref_id": "BIBREF60"}], "ref_spans": [], "section": "Streptokinase and Heparin were investigated as a treatment for patients infected by"}, {"text": "The first 20 patients were treated with heparin (10.000 IU) and the other 20 were treated with Streptokinase (250.000 IU). Each drug was prepared in a 3 ml volume of distilled water and nebulized for a period of 15 min every 4 h. The outcome of the study revealed an improvement of the hypoxemia as determined by PaO 2 /FiO 2 ratio >100, an improvement of the pulmonary compliance of the patient defined as dynamic compliance >50 ml/cm H 2 O, and a decrease of the occurrence of complications such as bleeding or coagulopathy within 72 h of initiation of therapy. Streptokinase and Heparin may prevent /or dissolve intra-alveolar fibrin clots respectively helping alveolar re-expansion (ClinicalTrials.gov; NCT03465085).", "cite_spans": [], "ref_spans": [], "section": "Streptokinase and Heparin were investigated as a treatment for patients infected by"}, {"text": "Methylprednisolone (81) is a natural products derivative (prednisolone derivative glucocorticoid) implemented by the FDA as an anticancer drug (Feinberg et al., 1957; Hall, 1992; Newman and Cragg, 2020; Ravina, 2011) . In early 2020, two clinical studies had been conducted on methylprednisolone against SARS-CoV-2 with 86 and 80 participants respectively. In both studies, all participants recovered except for one case that died in the first study (ClinicalTrials.gov; NCT04273321; NCT04244591). (Pillaiyar et al., 2020) . Nevertheless, many clinical studies were conducted on chloroquine as an anti-COVID-19 virus agent (ClinicalTrials.gov; NCT04303507), and its efficacy and safety remain unclear. It is proven highly effective in blocking viral replication in other infections including the SARS-associated coronavirus (CoV) (Cortegiani et al., 2020) . However, in a recent observational study, hydroxychloroquine treated patient was more seriously ill than those who hadn't received hydroxychloroquine (Geleris et al., 2020) .", "cite_spans": [{"start": 143, "end": 166, "text": "(Feinberg et al., 1957;", "ref_id": null}, {"start": 167, "end": 178, "text": "Hall, 1992;", "ref_id": "BIBREF19"}, {"start": 179, "end": 202, "text": "Newman and Cragg, 2020;", "ref_id": null}, {"start": 203, "end": 216, "text": "Ravina, 2011)", "ref_id": "BIBREF68"}, {"start": 498, "end": 522, "text": "(Pillaiyar et al., 2020)", "ref_id": "BIBREF66"}, {"start": 830, "end": 855, "text": "(Cortegiani et al., 2020)", "ref_id": "BIBREF7"}, {"start": 1008, "end": 1030, "text": "(Geleris et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "Streptokinase and Heparin were investigated as a treatment for patients infected by"}, {"text": "As discussed earlier, small-molecule, approved drugs, and natural products are promising entities to combat COVID-19 depending on various mechanisms of action.", "cite_spans": [], "ref_spans": [], "section": "Patents of natural products prescriptions against COVID-19 pandemic"}, {"text": "Traditional Chinese medicine (TCM) has a synergistic effect that plays a vital role in resisting the virus and resisting inflammation of the lung and thus some TCM formulas have been proposed and approved as patents against coronaviruses. Our review devotes to patents from natural product sources (Table 4 ).", "cite_spans": [], "ref_spans": [{"start": 298, "end": 306, "text": "(Table 4", "ref_id": "TABREF2"}], "section": "Patents of natural products prescriptions against COVID-19 pandemic"}, {"text": "One prescription for treating pneumonia caused by the new coronavirus infection was inspired by the TCM composition and discloses. The prescription raw materials combine, parts by weight, of the following TCM materials: 9 parts of Ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of Gypsum, 9 parts of Cassia Twig, 9 parts of Rhizoma Alismatis, 9 parts of Frifola, 9 parts of bighead Atractylodes rhizome, 15 parts of Poria cocos, 16 parts of Radix Bupleuri, 6 parts of Scutellaria baicalensis, 9 parts of ginger processed Pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of Flos Farae, 9 parts of Blackberry lily, 6 parts of Asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of ", "cite_spans": [], "ref_spans": [], "section": "Patents of natural products prescriptions against COVID-19 pandemic"}, {"text": "The consumption of healthy diets is one way to boost the immune system and in return help in fighting off viruses (Galanakis, 2020) . There is a wide range of plants that contribute to boosting the immune system given their high content of a wide variety of nutrients and biological active compounds (Sultan et al., 2014) . A strong immune system is essential for fighting against COVID-19. COVID-19 seems to be hazardous for people with comorbidities and those have a weaker immune system than healthy ones (N. Chen et al., 2020; Jiang et al., 2020) . Garlic stimulates the immune system as it is rich with a wide plethora of nutrients, vitamins, and sulfur-containing compounds (Iciek et al., 2009) . Certain vegetables such as broccoli, spinach and sweet potatoes are abundant with vitamin A which include retinol, retinoic acid and \u03b2-carotene. These fat-soluble compounds participate in enhancement of the immune function. Additionally, isotretinoin (vitamin A derivative), inhibits ACE2 and the entry of SARS-COV-2 into the body thereby lower the susceptibility to infections (Galanakis, 2020) . Citrus fruits are one of the best sources for vitamin C. Vitamin C increases the production of white blood cells providing a key role in fighting infections (Calder et al., 2020) . Vitamins are recommended for the protection against coronavirus as they increase patients' resistance against infection (Basiri, 2020).", "cite_spans": [{"start": 114, "end": 131, "text": "(Galanakis, 2020)", "ref_id": "BIBREF13"}, {"start": 300, "end": 321, "text": "(Sultan et al., 2014)", "ref_id": "BIBREF82"}, {"start": 508, "end": 530, "text": "(N. Chen et al., 2020;", "ref_id": null}, {"start": 531, "end": 550, "text": "Jiang et al., 2020)", "ref_id": "BIBREF35"}, {"start": 680, "end": 700, "text": "(Iciek et al., 2009)", "ref_id": "BIBREF27"}, {"start": 1081, "end": 1098, "text": "(Galanakis, 2020)", "ref_id": "BIBREF13"}, {"start": 1258, "end": 1279, "text": "(Calder et al., 2020)", "ref_id": null}], "ref_spans": [], "section": "The protective role of plants and their constituents against COVID-19"}, {"text": "The outbreak of COVID-19 has swept across the world rapidly spreading in a very alarming pace invading more than 200 countries, territories, areas leaving a trail of victims behind. Although SARS-CoV-2 is accompanied by symptoms similar to that of SARS-CoV-2 i.e. fever, cough, and fatigue, SARS-CoV-2 is far more contagious. It can be transmitted by droplets or close contact. Given the affinity by which SARS-CoV-2 protein S can bind to ACE2 receptors, human to human transmission seems to spread much faster than the common flu or even the previous coronaviruses. Thus, containing the outbreak is a burning issue requires extensive measures and developing specific safe drugs. Natural products have so far proven to be promising for the development of effective and less toxic antiviral agents. Owing to the genetic resemblance between coronaviruses, the drugs and antiviral agents which are usually effective against the other types of coronaviruses could be used to treat COVID-19. Some of the reported antivirals showed a promising antiviral activity against at least four types of human coronaviruses with significant EC 50 and CC 50 values. Other therapeutic agents have also been reported and are already moving into clinical trials including Xiyanping, fingolimod, methylprednisolone, streptokinase, and heparin. Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., Xiang, Z., Mu, Z., Chen, X., Chen, J., Hu, K., Jin, Q., Wang, J., Qian, Z., 2020.", "cite_spans": [], "ref_spans": [], "section": "Conclusions"}, {"text": "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1-12.", "cite_spans": [], "ref_spans": [], "section": "Conclusions"}, {"text": "Pan, Yaozong., Wang, Hengbin., Zhang, Dandan., Zhang, Bangguo., Li, Quan., Luo, Niancui., Cao, Zeqing., Zhai, Y., 2020 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al., 2020 ", "cite_spans": [{"start": 15, "end": 118, "text": "Wang, Hengbin., Zhang, Dandan., Zhang, Bangguo., Li, Quan., Luo, Niancui., Cao, Zeqing., Zhai, Y., 2020", "ref_id": null}, {"start": 128, "end": 227, "text": "Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al., 2020", "ref_id": null}], "ref_spans": [], "section": "Conclusions"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin", "authors": [{"first": "F", "middle": ["V"], "last": "Alonso-Caplen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Matsuoka", "suffix": ""}, {"first": "G", "middle": ["E"], "last": "Wilcox", "suffix": ""}, {"first": "R", "middle": ["W"], "last": "Compans", "suffix": ""}], "year": 1984, "venue": "Virus Res", "volume": "1", "issn": "", "pages": "153--167", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Quantitative antistreptokinase studies chemical drug therapeutics", "authors": [{"first": "H", "middle": ["C"], "last": "Anderson", "suffix": ""}, {"first": "H", "middle": ["G"], "last": "Kunkel", "suffix": ""}, {"first": "M", "middle": [], "last": "Mccarty", "suffix": ""}], "year": 1948, "venue": "Chem. Biol. Lett", "volume": "7", "issn": "", "pages": "63--72", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa", "authors": [{"first": "J", "middle": ["K"], "last": "Cho", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Curtis-Long", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Lee", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Kim", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Ryu", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Yuk", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Park", "suffix": ""}], "year": 2013, "venue": "Bioorg. Med. Chem", "volume": "21", "issn": "", "pages": "3051--3057", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Simultaneous determination of 9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate in rat plasma by UHPLC-ESI-MS/MS after administration of xiyanping injection: application to a pharmacokinetic study", "authors": [{"first": "L", "middle": [], "last": "Chong", "suffix": ""}, {"first": "W", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Luo", "suffix": ""}, {"first": "Z", "middle": [], "last": "Jiang", "suffix": ""}], "year": 2013, "venue": "Biomed. Chromatogr", "volume": "27", "issn": "", "pages": "825--830", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Glycyrrhizin, an active component of liquorice roots, and replication of SARSassociated coronavirus", "authors": [{"first": "J", "middle": [], "last": "Cinatl", "suffix": ""}, {"first": "B", "middle": [], "last": "Morgenstern", "suffix": ""}, {"first": "G", "middle": [], "last": "Bauer", "suffix": ""}, {"first": "P", "middle": [], "last": "Chandra", "suffix": ""}, {"first": "H", "middle": [], "last": "Rabenau", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Doerr", "suffix": ""}], "year": 2003, "venue": "Lancet", "volume": "361", "issn": "", "pages": "2045--2046", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Emergence of the Middle East respiratory syndrome coronavirus", "authors": [{"first": "C", "middle": ["M"], "last": "Coleman", "suffix": ""}, {"first": "M", "middle": ["B"], "last": "Frieman", "suffix": ""}], "year": 2013, "venue": "PLoS Pathog", "volume": "9", "issn": "", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Hosts and Sources of Endemic Human Coronaviruses", "authors": [{"first": "V", "middle": ["M"], "last": "Corman", "suffix": ""}, {"first": "D", "middle": [], "last": "Muth", "suffix": ""}, {"first": "D", "middle": [], "last": "Niemeyer", "suffix": ""}, {"first": "C", "middle": [], "last": "Drosten", "suffix": ""}], "year": 2018, "venue": "Adv. Virus Res", "volume": "100", "issn": "", "pages": "163--188", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19", "authors": [{"first": "A", "middle": [], "last": "Cortegiani", "suffix": ""}, {"first": "G", "middle": [], "last": "Ingoglia", "suffix": ""}, {"first": "M", "middle": [], "last": "Ippolito", "suffix": ""}, {"first": "A", "middle": [], "last": "Giarratano", "suffix": ""}, {"first": "S", "middle": [], "last": "Einav", "suffix": ""}], "year": 2020, "venue": "J. Crit. Care", "volume": "57", "issn": "", "pages": "279--283", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "The Rheumatologist's Role in Covid-19", "authors": [{"first": "R", "middle": ["Q"], "last": "Cron", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Chatham", "suffix": ""}], "year": 2020, "venue": "J. Rheumatol", "volume": "47", "issn": "", "pages": "639--642", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Glycyrrhiza glabra (Liquorice)-a potent medicinal herb", "authors": [{"first": "M", "middle": [], "last": "Damle", "suffix": ""}], "year": 2014, "venue": "Int. J. Herb. Med", "volume": "2", "issn": "", "pages": "132--136", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists", "authors": [{"first": "M", "middle": [], "last": "Day", "suffix": ""}], "year": 2020, "venue": "BMJ", "volume": "368", "issn": "", "pages": "", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals", "authors": [{"first": "J", "middle": [], "last": "Deng", "suffix": ""}, {"first": "", "middle": [], "last": "Jin", "suffix": ""}, {"first": "", "middle": [], "last": "Yipeng", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Sun", "suffix": ""}, {"first": "L", "middle": [], "last": "Hao", "suffix": ""}, {"first": "J", "middle": [], "last": "Bai", "suffix": ""}, {"first": "T", "middle": [], "last": "Huang", "suffix": ""}, {"first": "D", "middle": [], "last": "Lin", "suffix": ""}, {"first": "", "middle": [], "last": "Jin", "suffix": ""}, {"first": "", "middle": [], "last": "Yaping", "suffix": ""}, {"first": "K", "middle": [], "last": "Tian", "suffix": ""}], "year": 2020, "venue": "Transbound. Emerg. Dis", "volume": "67", "issn": "", "pages": "1745--1749", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Inhibitory activities of baicalin against renin and angiotensin-converting enzyme", "authors": [{"first": "Y", "middle": ["F"], "last": "Deng", "suffix": ""}, {"first": "R", "middle": ["E"], "last": "Aluko", "suffix": ""}, {"first": "Q", "middle": [], "last": "Jin", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "L", "middle": ["J"], "last": "Yuan", "suffix": ""}], "year": 2012, "venue": "Pharm. Biol", "volume": "50", "issn": "", "pages": "", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "The Food Systems in the Era of the Coronavirus (COVID-19) Pandemic Crisis", "authors": [{"first": "C", "middle": ["M"], "last": "Galanakis", "suffix": ""}], "year": 2020, "venue": "", "volume": "9", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "From SARS to MERS: evidence and speculation", "authors": [{"first": "H", "middle": [], "last": "Gao", "suffix": ""}, {"first": "H", "middle": [], "last": "Yao", "suffix": ""}, {"first": "S", "middle": [], "last": "Yang", "suffix": ""}, {"first": "L", "middle": [], "last": "Li", "suffix": ""}], "year": 2016, "venue": "Front. Med", "volume": "10", "issn": "", "pages": "377--382", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Prescription for treating pneumonia caused by novel coronavirus infection and application thereof", "authors": [{"first": "Y", "middle": [], "last": "Ge", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Minor alkaloids of Tylophora asthmatica: Revised structure of tylophorinidine", "authors": [{"first": "T", "middle": ["R"], "last": "Govindachari", "suffix": ""}, {"first": "N", "middle": [], "last": "Viswanathan", "suffix": ""}, {"first": "J", "middle": [], "last": "Radhakrishnan", "suffix": ""}, {"first": "B", "middle": ["R"], "last": "Pai", "suffix": ""}, {"first": "S", "middle": [], "last": "Natarajan", "suffix": ""}, {"first": "P", "middle": ["S"], "last": "Subramaniam", "suffix": ""}], "year": 1973, "venue": "Tetrahedron", "volume": "29", "issn": "", "pages": "891--897", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "The neuroprotective pharmacology of methylprednisolone", "authors": [{"first": "E", "middle": ["D"], "last": "Hall", "suffix": ""}], "year": 1992, "venue": "J. Neurosurg", "volume": "76", "issn": "", "pages": "13--22", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Interferon-B and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays", "authors": [{"first": "B", "middle": ["J"], "last": "Hart", "suffix": ""}, {"first": "J", "middle": [], "last": "Dyall", "suffix": ""}, {"first": "E", "middle": [], "last": "Postnikova", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "J", "middle": [], "last": "Kindrachuk", "suffix": ""}, {"first": "R", "middle": ["F"], "last": "Johnson", "suffix": ""}, {"first": "G", "middle": ["G"], "last": "Olinger", "suffix": ""}, {"first": "M", "middle": ["B"], "last": "Frieman", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Holbrook", "suffix": ""}, {"first": "P", "middle": ["B"], "last": "Jahrling", "suffix": ""}, {"first": "L", "middle": [], "last": "Hensley", "suffix": ""}], "year": 2014, "venue": "J. Gen. Virol", "volume": "95", "issn": "", "pages": "571--577", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Coronavirus Disease 2019 (COVID-19): What we know?", "authors": [{"first": "F", "middle": [], "last": "He", "suffix": ""}, {"first": "Y", "middle": [], "last": "Deng", "suffix": ""}, {"first": "W", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "J. Med. Virol", "volume": "92", "issn": "", "pages": "719--725", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine", "authors": [{"first": "Y", "middle": [], "last": "He", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "S", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Z", "middle": [], "last": "Kou", "suffix": ""}, {"first": "W", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": [], "last": "Farzan", "suffix": ""}, {"first": "S", "middle": [], "last": "Jiang", "suffix": ""}], "year": 2004, "venue": "Biochem. Biophys. Res. Commun", "volume": "324", "issn": "", "pages": "773--781", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses", "authors": [{"first": "R", "middle": [], "last": "Hilgenfeld", "suffix": ""}, {"first": "M", "middle": [], "last": "Peiris", "suffix": ""}], "year": 2013, "venue": "Antiviral Res", "volume": "100", "issn": "", "pages": "286--295", "other_ids": {}}, "BIBREF26": {"ref_id": "b26", "title": "COVID-19 Spikehost cell receptor GRP78 binding site prediction", "authors": [{"first": "I", "middle": ["M"], "last": "Ibrahim", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Abdelmalek", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Elshahat", "suffix": ""}, {"first": "A", "middle": ["A"], "last": "Elfiky", "suffix": ""}], "year": 2020, "venue": "J. Infect", "volume": "80", "issn": "", "pages": "554--562", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "Biological properties of garlic and garlicderived organosulfur compounds", "authors": [{"first": "M", "middle": [], "last": "Iciek", "suffix": ""}, {"first": "I", "middle": [], "last": "Kwiecie\u0144", "suffix": ""}, {"first": "L", "middle": [], "last": "W\u0142odek", "suffix": ""}], "year": 2009, "venue": "Environ. Mol. Mutagen", "volume": "50", "issn": "", "pages": "247--265", "other_ids": {}}, "BIBREF29": {"ref_id": "b29", "title": "Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy", "authors": [{"first": "J", "middle": [], "last": "Ingwersen", "suffix": ""}, {"first": "O", "middle": [], "last": "Aktas", "suffix": ""}, {"first": "P", "middle": [], "last": "Kuery", "suffix": ""}, {"first": "B", "middle": [], "last": "Kieseier", "suffix": ""}, {"first": "A", "middle": [], "last": "Boyko", "suffix": ""}, {"first": "H.-P", "middle": [], "last": "Hartung", "suffix": ""}], "year": 2012, "venue": "Clin. Immunol", "volume": "142", "issn": "", "pages": "15--24", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data", "authors": [{"first": "M", "middle": ["T"], "last": "Islam", "suffix": ""}, {"first": "C", "middle": [], "last": "Sarkar", "suffix": ""}, {"first": "D", "middle": ["M"], "last": "El-Kersh", "suffix": ""}, {"first": "S", "middle": [], "last": "Jamaddar", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Uddin", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Shilpi", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Mubarak", "suffix": ""}], "year": 2020, "venue": "Phyther. Res", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF32": {"ref_id": "b32", "title": "A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes", "authors": [{"first": "K", "middle": ["J"], "last": "Jarvill-Taylor", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Anderson", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Graves", "suffix": ""}], "year": 2001, "venue": "J. Am", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human", "authors": [{"first": "W", "middle": [], "last": "Ji", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "J", "middle": [], "last": "Zai", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "J. Med. Virol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF35": {"ref_id": "b35", "title": "Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)", "authors": [{"first": "F", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "L", "middle": [], "last": "Deng", "suffix": ""}, {"first": "L", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cai", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Cheung", "suffix": ""}, {"first": "Z", "middle": [], "last": "Xia", "suffix": ""}], "year": 2020, "venue": "J. Gen. Intern", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF37": {"ref_id": "b37", "title": "History and recent advances in coronavirus discovery", "authors": [{"first": "J", "middle": ["S"], "last": "Kahn", "suffix": ""}, {"first": "K", "middle": [], "last": "Mcintosh", "suffix": ""}], "year": 2005, "venue": "Pediatr. Infect. Dis. J", "volume": "24", "issn": "", "pages": "223--227", "other_ids": {}}, "BIBREF38": {"ref_id": "b38", "title": "Phytochemical analysis and antileukemic activity of polyphenolic constituents of Toona sinensis", "authors": [{"first": "A", "middle": [], "last": "Kakumu", "suffix": ""}, {"first": "M", "middle": [], "last": "Ninomiya", "suffix": ""}, {"first": "M", "middle": [], "last": "Efdi", "suffix": ""}, {"first": "M", "middle": [], "last": "Adfa", "suffix": ""}, {"first": "M", "middle": [], "last": "Hayashi", "suffix": ""}, {"first": "K", "middle": [], "last": "Tanaka", "suffix": ""}, {"first": "M", "middle": [], "last": "Koketsu", "suffix": ""}], "year": 2014, "venue": "Bioorg. Med. Chem. Lett", "volume": "24", "issn": "", "pages": "4286--4290", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "A well infant with coronavirus disease 2019 (COVID-19) with high viral load", "authors": [{"first": "K.-Q", "middle": [], "last": "Kam", "suffix": ""}, {"first": "C", "middle": ["F"], "last": "Yung", "suffix": ""}, {"first": "L", "middle": [], "last": "Cui", "suffix": ""}, {"first": "R", "middle": [], "last": "Lin Tzer Pin", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Mak", "suffix": ""}, {"first": "M", "middle": [], "last": "Maiwald", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "C", "middle": ["Y"], "last": "Chong", "suffix": ""}, {"first": "K", "middle": [], "last": "Nadua", "suffix": ""}, {"first": "N", "middle": ["W H"], "last": "Tan", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Thoon", "suffix": ""}], "year": 2020, "venue": "Clin. Infect. Dis", "volume": "71", "issn": "", "pages": "", "other_ids": {}}, "BIBREF40": {"ref_id": "b40", "title": "Incubation periods of acute respiratory viral infections: a systematic review", "authors": [{"first": "J", "middle": [], "last": "Lessler", "suffix": ""}, {"first": "N", "middle": ["G"], "last": "Reich", "suffix": ""}, {"first": "R", "middle": [], "last": "Brookmeyer", "suffix": ""}, {"first": "T", "middle": ["M"], "last": "Perl", "suffix": ""}, {"first": "K", "middle": ["E"], "last": "Nelson", "suffix": ""}, {"first": "D", "middle": ["A T"], "last": "Cummings", "suffix": ""}], "year": 2009, "venue": "Lancet Infect. Dis", "volume": "9", "issn": "", "pages": "291--300", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "Mass masking in the COVID-19 epidemic: people need guidance", "authors": [{"first": "C", "middle": ["C"], "last": "Leung", "suffix": ""}, {"first": "T", "middle": ["H"], "last": "Lam", "suffix": ""}, {"first": "K", "middle": ["K"], "last": "Cheng", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review", "authors": [{"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yan", "suffix": ""}, {"first": "H", "middle": [], "last": "Sun", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "C", "middle": [], "last": "Su", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "J", "middle": [], "last": "Zhang", "suffix": ""}], "year": 2019, "venue": "Front. Pharmacol", "volume": "10", "issn": "", "pages": "", "other_ids": {}}, "BIBREF43": {"ref_id": "b43", "title": "Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia", "authors": [{"first": "Q", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Guan", "suffix": ""}, {"first": "P", "middle": [], "last": "Wu", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "L", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "Y", "middle": [], "last": "Tong", "suffix": ""}, {"first": "R", "middle": [], "last": "Ren", "suffix": ""}, {"first": "K", "middle": ["S M"], "last": "Leung", "suffix": ""}, {"first": "E", "middle": ["H Y"], "last": "Lau", "suffix": ""}, {"first": "J", "middle": ["Y"], "last": "Wong", "suffix": ""}], "year": 2020, "venue": "N. Engl. J. Med", "volume": "382", "issn": "", "pages": "1199--1207", "other_ids": {}}, "BIBREF44": {"ref_id": "b44", "title": "Identification of natural compounds with antiviral activities against SARS-associated coronavirus", "authors": [{"first": "S", "middle": [], "last": "Li", "suffix": ""}, {"first": "C", "middle": [], "last": "Chen", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Guo", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "L", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": [], "last": "Hua", "suffix": ""}, {"first": "J", "middle": [], "last": "Yu", "suffix": ""}, {"first": "P", "middle": [], "last": "Xiao", "suffix": ""}, {"first": "R", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Tan", "suffix": ""}], "year": 2005, "venue": "Antiviral Res", "volume": "67", "issn": "", "pages": "18--23", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", "authors": [{"first": "W", "middle": [], "last": "Li", "suffix": ""}, {"first": "M", "middle": ["J"], "last": "Moore", "suffix": ""}, {"first": "N", "middle": [], "last": "Vasilieva", "suffix": ""}, {"first": "J", "middle": [], "last": "Sui", "suffix": ""}, {"first": "S", "middle": ["K"], "last": "Wong", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Berne", "suffix": ""}, {"first": "M", "middle": [], "last": "Somasundaran", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Sullivan", "suffix": ""}, {"first": "K", "middle": [], "last": "Luzuriaga", "suffix": ""}, {"first": "T", "middle": ["C"], "last": "Greenough", "suffix": ""}, {"first": "H", "middle": [], "last": "Choe", "suffix": ""}, {"first": "M", "middle": [], "last": "Farzan", "suffix": ""}], "year": 2003, "venue": "Nature", "volume": "426", "issn": "", "pages": "450--454", "other_ids": {}}, "BIBREF47": {"ref_id": "b47", "title": "Preparative isolation and purification of four compounds from Chinese medicinal herb Gentiana scabra Bunge by high-speed countercurrent chromatography", "authors": [{"first": "Y", "middle": [], "last": "Liang", "suffix": ""}, {"first": "J", "middle": [], "last": "Hu", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "T", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ito", "suffix": ""}], "year": 2007, "venue": "J. Liq. Chromatogr. Relat. Technol", "volume": "30", "issn": "", "pages": "509--520", "other_ids": {}}, "BIBREF48": {"ref_id": "b48", "title": "Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds", "authors": [{"first": "C.-W", "middle": [], "last": "Lin", "suffix": ""}, {"first": "F.-J", "middle": [], "last": "Tsai", "suffix": ""}, {"first": "C.-H", "middle": [], "last": "Tsai", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Lai", "suffix": ""}, {"first": "L", "middle": [], "last": "Wan", "suffix": ""}, {"first": "T.-Y", "middle": [], "last": "Ho", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Hsieh", "suffix": ""}, {"first": "P.-D", "middle": ["L"], "last": "Chao", "suffix": ""}], "year": 2005, "venue": "Antiviral Res", "volume": "68", "issn": "", "pages": "36--42", "other_ids": {}}, "BIBREF49": {"ref_id": "b49", "title": "Antiviral natural products and herbal medicines", "authors": [{"first": "L.-T", "middle": [], "last": "Lin", "suffix": ""}, {"first": "W.-C", "middle": [], "last": "Hsu", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Lin", "suffix": ""}], "year": 2014, "venue": "J. Tradit. Complement. Med", "volume": "4", "issn": "", "pages": "24--35", "other_ids": {}}, "BIBREF50": {"ref_id": "b50", "title": "Hypothesis for potential pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral pneumonia", "authors": [{"first": "L", "middle": [], "last": "Lin", "suffix": ""}, {"first": "L", "middle": [], "last": "Lu", "suffix": ""}, {"first": "W", "middle": [], "last": "Cao", "suffix": ""}, {"first": "T", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "Emerg. Microbes Infect", "volume": "9", "issn": "", "pages": "727--732", "other_ids": {}}, "BIBREF52": {"ref_id": "b52", "title": "protease inhibitor isolated from the marine sponge Axinella cf. corrugata: structure elucidation and synthesis", "authors": [], "year": null, "venue": "J. Braz. Chem. Soc", "volume": "18", "issn": "", "pages": "440--443", "other_ids": {}}, "BIBREF53": {"ref_id": "b53", "title": "Liquid chromatography-tandem mass spectrometry method for determination of N-acetylglucosamine concentration in human plasma", "authors": [{"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "Z", "middle": [], "last": "Li", "suffix": ""}, {"first": "G", "middle": [], "last": "Liu", "suffix": ""}, {"first": "J", "middle": [], "last": "Jia", "suffix": ""}, {"first": "S", "middle": [], "last": "Li", "suffix": ""}, {"first": "C", "middle": [], "last": "Yu", "suffix": ""}], "year": 2008, "venue": "J. Chromatogr. B", "volume": "862", "issn": "", "pages": "150--154", "other_ids": {}}, "BIBREF55": {"ref_id": "b55", "title": "Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species", "authors": [{"first": "M", "middle": ["R"], "last": "Loizzo", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Saab", "suffix": ""}, {"first": "R", "middle": [], "last": "Tundis", "suffix": ""}, {"first": "G", "middle": ["A"], "last": "Statti", "suffix": ""}, {"first": "F", "middle": [], "last": "Menichini", "suffix": ""}, {"first": "I", "middle": [], "last": "Lampronti", "suffix": ""}, {"first": "R", "middle": [], "last": "Gambari", "suffix": ""}, {"first": "J", "middle": [], "last": "Cinatl", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Doerr", "suffix": ""}], "year": 2008, "venue": "Chem. Biodivers", "volume": "5", "issn": "", "pages": "461--470", "other_ids": {}}, "BIBREF56": {"ref_id": "b56", "title": "Structure and antimicrobial properties of monensin A and its derivatives: summary of the achievements", "authors": [{"first": "D", "middle": [], "last": "\u0141owicki", "suffix": ""}, {"first": "A", "middle": [], "last": "Huczy\u0144ski", "suffix": ""}], "year": 2013, "venue": "Biomed Res. Int", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF57": {"ref_id": "b57", "title": "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", "authors": [{"first": "R", "middle": [], "last": "Lu", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "J", "middle": [], "last": "Li", "suffix": ""}, {"first": "P", "middle": [], "last": "Niu", "suffix": ""}, {"first": "B", "middle": [], "last": "Yang", "suffix": ""}, {"first": "H", "middle": [], "last": "Wu", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Song", "suffix": ""}, {"first": "B", "middle": [], "last": "Huang", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhu", "suffix": ""}], "year": 2020, "venue": "Lancet", "volume": "395", "issn": "", "pages": "565--574", "other_ids": {}}, "BIBREF58": {"ref_id": "b58", "title": "Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs", "authors": [{"first": "H", "middle": [], "last": "Luo", "suffix": ""}, {"first": "Q", "middle": [], "last": "Tang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shang", "suffix": ""}, {"first": "S", "middle": [], "last": "Liang", "suffix": ""}, {"first": "M", "middle": [], "last": "Yang", "suffix": ""}, {"first": "N", "middle": [], "last": "Robinson", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "Chin. J. Integr. Med", "volume": "26", "issn": "", "pages": "243--250", "other_ids": {}}, "BIBREF59": {"ref_id": "b59", "title": "Slew of trials launch to test coronavirus treatments in China", "authors": [{"first": "A", "middle": [], "last": "Maxmen", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "578", "issn": "", "pages": "347--348", "other_ids": {}}, "BIBREF60": {"ref_id": "b60", "title": "The discovery of heparin", "authors": [{"first": "J", "middle": ["A Y"], "last": "Mclean", "suffix": ""}], "year": 1959, "venue": "Circulation", "volume": "19", "issn": "", "pages": "75--78", "other_ids": {}}, "BIBREF61": {"ref_id": "b61", "title": "Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulinpreventing and treating viral diseases and application thereof", "authors": [{"first": "Z", "middle": [], "last": "Meng", "suffix": ""}, {"first": "T", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Ma", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "C", "middle": [], "last": "Van Ness", "suffix": ""}, {"first": "Y", "middle": [], "last": "Gan", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "J", "middle": [], "last": "Tang", "suffix": ""}, {"first": "G", "middle": [], "last": "Lou", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "J", "middle": [], "last": "Wu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yen", "suffix": ""}, {"first": "R", "middle": [], "last": "Xu", "suffix": ""}, {"first": "W", "middle": [], "last": "Huang", "suffix": ""}], "year": 2013, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF62": {"ref_id": "b62", "title": "Asymptomatic cases in a family cluster with SARS-CoV-2 infection", "authors": [{"first": "X", "middle": [], "last": "Pan", "suffix": ""}, {"first": "D", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xia", "suffix": ""}, {"first": "X", "middle": [], "last": "Wu", "suffix": ""}, {"first": "T", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Ou", "suffix": ""}, {"first": "L", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "J", "middle": [], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "Lancet Infect. Dis", "volume": "395", "issn": "", "pages": "514--523", "other_ids": {}}, "BIBREF63": {"ref_id": "b63", "title": "Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors", "authors": [{"first": "J.-Y", "middle": [], "last": "Park", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Yuk", "suffix": ""}, {"first": "H", "middle": ["W"], "last": "Ryu", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Lim", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Kim", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Park", "suffix": ""}, {"first": "Y", "middle": ["B"], "last": "Ryu", "suffix": ""}, {"first": "W", "middle": ["S"], "last": "Lee", "suffix": ""}], "year": 2017, "venue": "J. Enzyme Inhib. Med. Chem", "volume": "32", "issn": "", "pages": "504--512", "other_ids": {}}, "BIBREF64": {"ref_id": "b64", "title": "Cassia tora Linn.: An overview", "authors": [{"first": "H", "middle": ["A"], "last": "Pawar", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "D&apos;mello", "suffix": ""}], "year": 2011, "venue": "Int. J. Pharm. Sci. Res", "volume": "2", "issn": "", "pages": "2286--2291", "other_ids": {}}, "BIBREF65": {"ref_id": "b65", "title": "Coronavirus as a possible cause of severe acute respiratory syndrome", "authors": [{"first": "J", "middle": ["S M"], "last": "Peiris", "suffix": ""}, {"first": "S", "middle": ["T"], "last": "Lai", "suffix": ""}, {"first": "L", "middle": ["L M"], "last": "Poon", "suffix": ""}, {"first": "Y", "middle": [], "last": "Guan", "suffix": ""}, {"first": "L", "middle": ["Y C"], "last": "Yam", "suffix": ""}, {"first": "W", "middle": [], "last": "Lim", "suffix": ""}, {"first": "J", "middle": [], "last": "Nicholls", "suffix": ""}, {"first": "W", "middle": ["K S"], "last": "Yee", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Yan", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Cheung", "suffix": ""}], "year": 2003, "venue": "Lancet", "volume": "361", "issn": "", "pages": "1319--1325", "other_ids": {}}, "BIBREF66": {"ref_id": "b66", "title": "Recent discovery and development of inhibitors targeting coronaviruses", "authors": [{"first": "T", "middle": [], "last": "Pillaiyar", "suffix": ""}, {"first": "S", "middle": [], "last": "Meenakshisundaram", "suffix": ""}, {"first": "M", "middle": [], "last": "Manickam", "suffix": ""}], "year": 2020, "venue": "Drug Discov. Today", "volume": "25", "issn": "", "pages": "668--688", "other_ids": {}}, "BIBREF68": {"ref_id": "b68", "title": "The evolution of drug discovery: from traditional medicines to modern drugs", "authors": [{"first": "E", "middle": [], "last": "Ravina", "suffix": ""}], "year": 2011, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF69": {"ref_id": "b69", "title": "Modulation of humoral and cell-mediated immune responses by Azadirachta indica (Neem) in mice", "authors": [{"first": "A", "middle": [], "last": "Ray", "suffix": ""}, {"first": "B", "middle": ["D"], "last": "Banerjee", "suffix": ""}, {"first": "P", "middle": [], "last": "Sen", "suffix": ""}], "year": 1996, "venue": "Indian J. Exp. Biol", "volume": "34", "issn": "", "pages": "698--701", "other_ids": {}}, "BIBREF70": {"ref_id": "b70", "title": "Counting on natural products for drug design", "authors": [{"first": "T", "middle": [], "last": "Rodrigues", "suffix": ""}, {"first": "D", "middle": [], "last": "Reker", "suffix": ""}, {"first": "P", "middle": [], "last": "Schneider", "suffix": ""}, {"first": "G", "middle": [], "last": "Schneider", "suffix": ""}], "year": 2016, "venue": "Nat. Chem", "volume": "8", "issn": "", "pages": "531--541", "other_ids": {}}, "BIBREF71": {"ref_id": "b71", "title": "The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak", "authors": [{"first": "H", "middle": ["A"], "last": "Rothan", "suffix": ""}, {"first": "S", "middle": ["N"], "last": "Byrareddy", "suffix": ""}], "year": 2020, "venue": "J. Autoimmun", "volume": "109", "issn": "", "pages": "", "other_ids": {}}, "BIBREF72": {"ref_id": "b72", "title": "SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii", "authors": [{"first": "Y", "middle": ["B"], "last": "Ryu", "suffix": ""}, {"first": "S.-J", "middle": [], "last": "Park", "suffix": ""}, {"first": "Y", "middle": ["M"], "last": "Kim", "suffix": ""}, {"first": "J.-Y", "middle": [], "last": "Lee", "suffix": ""}, {"first": "W", "middle": ["D"], "last": "Seo", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Chang", "suffix": ""}, {"first": "K", "middle": ["H"], "last": "Park", "suffix": ""}, {"first": "M.-C", "middle": [], "last": "Rho", "suffix": ""}, {"first": "W", "middle": ["S"], "last": "Lee", "suffix": ""}], "year": 2010, "venue": "Bioorg. Med. Chem. Lett", "volume": "20", "issn": "", "pages": "1873--1876", "other_ids": {}}, "BIBREF73": {"ref_id": "b73", "title": "Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature", "authors": [{"first": "A", "middle": ["R"], "last": "Sahin", "suffix": ""}, {"first": "A", "middle": [], "last": "Erdogan", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Agaoglu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Dineri", "suffix": ""}, {"first": "A", "middle": ["Y"], "last": "Cakirci", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Senel", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Okyay", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Tasdogan", "suffix": ""}], "year": 2019, "venue": "", "volume": "4", "issn": "", "pages": "1--7", "other_ids": {}}, "BIBREF74": {"ref_id": "b74", "title": "Therapeutic basis of glycyrrhizin on chronic hepatitis B", "authors": [{"first": "H", "middle": [], "last": "Sato", "suffix": ""}, {"first": "W", "middle": [], "last": "Goto", "suffix": ""}, {"first": "J", "middle": [], "last": "Yamamura", "suffix": ""}, {"first": "M", "middle": [], "last": "Kurokawa", "suffix": ""}, {"first": "S", "middle": [], "last": "Kageyama", "suffix": ""}, {"first": "T", "middle": [], "last": "Takahara", "suffix": ""}, {"first": "A", "middle": [], "last": "Watanabe", "suffix": ""}, {"first": "K", "middle": [], "last": "Shiraki", "suffix": ""}], "year": 1996, "venue": "Antiviral Res", "volume": "30", "issn": "", "pages": "171--177", "other_ids": {}}, "BIBREF75": {"ref_id": "b75", "title": "High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses", "authors": [{"first": "L", "middle": [], "last": "Shen", "suffix": ""}, {"first": "J", "middle": [], "last": "Niu", "suffix": ""}, {"first": "C", "middle": [], "last": "Wang", "suffix": ""}, {"first": "B", "middle": [], "last": "Huang", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}, {"first": "N", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Deng", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}, {"first": "F", "middle": [], "last": "Ye", "suffix": ""}, {"first": "S", "middle": [], "last": "Cen", "suffix": ""}, {"first": "T", "middle": [], "last": "Wenjie", "suffix": ""}], "year": 2019, "venue": "J. Virol", "volume": "93", "issn": "", "pages": "23--42", "other_ids": {}}, "BIBREF76": {"ref_id": "b76", "title": "Clinical isolates of human coronavirus 229E bypass the endosome for cell entry", "authors": [{"first": "K", "middle": [], "last": "Shirato", "suffix": ""}, {"first": "K", "middle": [], "last": "Kanou", "suffix": ""}, {"first": "M", "middle": [], "last": "Kawase", "suffix": ""}, {"first": "S", "middle": [], "last": "Matsuyama", "suffix": ""}], "year": 2017, "venue": "J. Virol", "volume": "91", "issn": "", "pages": "1387--1403", "other_ids": {}}, "BIBREF77": {"ref_id": "b77", "title": "vitro antiviral activity of Echinaforce\u00ae, an Echinacea purpurea preparation, against common cold coronavirus 229E and highly pathogenic MERS-CoV and SARS-CoV. Virology", "authors": [{"first": "J", "middle": [], "last": "Signer", "suffix": ""}, {"first": "H", "middle": ["R"], "last": "Jonsdottir", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Albrich", "suffix": ""}, {"first": "M", "middle": [], "last": "Strasser", "suffix": ""}, {"first": "R", "middle": [], "last": "Z\u00fcst", "suffix": ""}, {"first": "S", "middle": [], "last": "Ryter", "suffix": ""}, {"first": "R", "middle": [], "last": "Ackermann-G\u00e4umann", "suffix": ""}, {"first": "N", "middle": [], "last": "Lenz", "suffix": ""}, {"first": "D", "middle": [], "last": "Siegrist", "suffix": ""}, {"first": "A", "middle": [], "last": "Suter", "suffix": ""}, {"first": "R", "middle": [], "last": "Schoop", "suffix": ""}, {"first": "O", "middle": ["B"], "last": "Engler", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF78": {"ref_id": "b78", "title": "A Review of Coronavirus Disease-2019 (COVID-19)", "authors": [{"first": "T", "middle": [], "last": "Singhal", "suffix": ""}], "year": 2020, "venue": "Indian J. Pediatr", "volume": "", "issn": "", "pages": "1--6", "other_ids": {}}, "BIBREF79": {"ref_id": "b79", "title": "Cycloheximide and other glutarimide antibiotics", "authors": [{"first": "H", "middle": ["D"], "last": "Sisler", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Siegel", "suffix": ""}], "year": 1967, "venue": "Mechanism of Action", "volume": "", "issn": "", "pages": "283--307", "other_ids": {}}, "BIBREF80": {"ref_id": "b80", "title": "World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)", "authors": [{"first": "C", "middle": [], "last": "Sohrabi", "suffix": ""}, {"first": "Z", "middle": [], "last": "Alsafi", "suffix": ""}, {"first": "N", "middle": [], "last": "O&apos;neill", "suffix": ""}, {"first": "M", "middle": [], "last": "Khan", "suffix": ""}, {"first": "A", "middle": [], "last": "Kerwan", "suffix": ""}, {"first": "A", "middle": [], "last": "Al-Jabir", "suffix": ""}, {"first": "C", "middle": [], "last": "Iosifidis", "suffix": ""}, {"first": "R", "middle": [], "last": "Agha", "suffix": ""}], "year": 2020, "venue": "Int. J. Surg", "volume": "76", "issn": "", "pages": "71--76", "other_ids": {}}, "BIBREF81": {"ref_id": "b81", "title": "Mycophenolates in transplantation", "authors": [{"first": "H", "middle": ["W"], "last": "Sollinger", "suffix": ""}], "year": 2004, "venue": "Clin. Transplant", "volume": "18", "issn": "", "pages": "485--492", "other_ids": {}}, "BIBREF82": {"ref_id": "b82", "title": "Immunity: Plants as Effective Mediators", "authors": [{"first": "M", "middle": ["T"], "last": "Sultan", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Buttxs", "suffix": ""}, {"first": "M", "middle": ["M N"], "last": "Qayyum", "suffix": ""}, {"first": "H", "middle": ["A R"], "last": "Suleria", "suffix": ""}], "year": 2014, "venue": "Crit. Rev. Food Sci. Nutr", "volume": "54", "issn": "", "pages": "1298--1308", "other_ids": {}}, "BIBREF84": {"ref_id": "b84", "title": "The pediatric burden of human coronaviruses evaluated for 20 years", "authors": [{"first": "H", "middle": ["K"], "last": "Talbot", "suffix": ""}, {"first": "B", "middle": ["E"], "last": "Shepherd", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Crowe", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Griffin", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Edwards", "suffix": ""}, {"first": "A", "middle": ["B"], "last": "Podsiad", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Tollefson", "suffix": ""}, {"first": "P", "middle": ["F"], "last": "Wright", "suffix": ""}, {"first": "J", "middle": [], "last": "Williams", "suffix": ""}], "year": 2009, "venue": "Pediatr. Infect. Dis. J", "volume": "28", "issn": "", "pages": "", "other_ids": {}}, "BIBREF85": {"ref_id": "b85", "title": "Of chloroquine and COVID-19", "authors": [{"first": "F", "middle": [], "last": "Touret", "suffix": ""}, {"first": "X", "middle": [], "last": "De Lamballerie", "suffix": ""}], "year": 2020, "venue": "Antiviral Res", "volume": "177", "issn": "", "pages": "", "other_ids": {}}, "BIBREF86": {"ref_id": "b86", "title": "Severe acute respiratory syndrome: clinical outcome and prognostic correlates", "authors": [{"first": "P", "middle": ["T"], "last": "Tsui", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Kwok", "suffix": ""}, {"first": "H", "middle": [], "last": "Yuen", "suffix": ""}, {"first": "S", "middle": ["T"], "last": "Lai", "suffix": ""}, {"first": "L", "middle": [], "last": "Van Der Hoek", "suffix": ""}, {"first": "K", "middle": [], "last": "Pyrc", "suffix": ""}, {"first": "M", "middle": ["F"], "last": "Jebbink", "suffix": ""}, {"first": "W", "middle": [], "last": "Vermeulen-Oost", "suffix": ""}, {"first": "R", "middle": ["J M"], "last": "Berkhout", "suffix": ""}, {"first": "K", "middle": ["C"], "last": "Wolthers", "suffix": ""}, {"first": "P", "middle": ["M E"], "last": "Wertheim-Van Dillen", "suffix": ""}, {"first": "J", "middle": [], "last": "Kaandorp", "suffix": ""}, {"first": "J", "middle": [], "last": "Spaargaren", "suffix": ""}], "year": null, "venue": "Emerg. Infect. Dis", "volume": "9", "issn": "", "pages": "368--373", "other_ids": {}}, "BIBREF87": {"ref_id": "b87", "title": "The Chemistry of Antimycin AX Structure of the Antimycins1", "authors": [{"first": "E", "middle": ["E"], "last": "Van Tamelen", "suffix": ""}, {"first": "J", "middle": ["P"], "last": "Dickie", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Loomans", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Dewey", "suffix": ""}, {"first": "F", "middle": ["M"], "last": "Strong", "suffix": ""}], "year": 1961, "venue": "J. Am. Chem. Soc", "volume": "83", "issn": "", "pages": "1639--1646", "other_ids": {}}, "BIBREF88": {"ref_id": "b88", "title": "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", "authors": [{"first": "A", "middle": ["C"], "last": "Walls", "suffix": ""}, {"first": "Y.-J", "middle": [], "last": "Park", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Tortorici", "suffix": ""}, {"first": "A", "middle": [], "last": "Wall", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Mcguire", "suffix": ""}, {"first": "D", "middle": [], "last": "Veesler", "suffix": ""}], "year": 2020, "venue": "Cell", "volume": "181", "issn": "", "pages": "281--292", "other_ids": {}}, "BIBREF89": {"ref_id": "b89", "title": "Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations", "authors": [{"first": "E", "middle": ["E"], "last": "Walsh", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Shin", "suffix": ""}, {"first": "A", "middle": ["R"], "last": "Falsey", "suffix": ""}], "year": 2013, "venue": "J. Infect. Dis", "volume": "208", "issn": "", "pages": "1634--1642", "other_ids": {}}, "BIBREF90": {"ref_id": "b90", "title": "Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing", "authors": [{"first": "S", "middle": [], "last": "Wan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xiang", "suffix": ""}, {"first": "W", "middle": [], "last": "Fang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "B", "middle": [], "last": "Li", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}, {"first": "C", "middle": [], "last": "Lang", "suffix": ""}, {"first": "D", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Q", "middle": [], "last": "Sun", "suffix": ""}, {"first": "Y", "middle": [], "last": "Xiong", "suffix": ""}], "year": 2020, "venue": "J. Med. Virol", "volume": "92", "issn": "", "pages": "797--806", "other_ids": {}}, "BIBREF91": {"ref_id": "b91", "title": "Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus", "authors": [{"first": "Y", "middle": [], "last": "Wan", "suffix": ""}, {"first": "J", "middle": [], "last": "Shang", "suffix": ""}, {"first": "R", "middle": [], "last": "Graham", "suffix": ""}, {"first": "R", "middle": ["S"], "last": "Baric", "suffix": ""}, {"first": "F", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "J. Virol", "volume": "94", "issn": "", "pages": "", "other_ids": {}}, "BIBREF92": {"ref_id": "b92", "title": "Sachet for efficiently preventing novel coronavirus pneumonia and influenza", "authors": [{"first": "Xuechang", "middle": [";"], "last": "Wang", "suffix": ""}, {"first": "", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "S", "middle": [], "last": "Cheng", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF93": {"ref_id": "b93", "title": "A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence", "authors": [{"first": "L", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "D", "middle": [], "last": "Ye", "suffix": ""}, {"first": "Q", "middle": [], "last": "Liu", "suffix": ""}], "year": 2020, "venue": "Int. J. Antimicrob. Agents", "volume": "55", "issn": "", "pages": "", "other_ids": {}}, "BIBREF94": {"ref_id": "b94", "title": "Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus", "authors": [{"first": "C.-C", "middle": [], "last": "Wen", "suffix": ""}, {"first": "Y.-H", "middle": [], "last": "Kuo", "suffix": ""}, {"first": "J.-T", "middle": [], "last": "Jan", "suffix": ""}, {"first": "P.-H", "middle": [], "last": "Liang", "suffix": ""}, {"first": "S.-Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H.-G", "middle": [], "last": "Liu", "suffix": ""}, {"first": "C.-K", "middle": [], "last": "Lee", "suffix": ""}, {"first": "S.-T", "middle": [], "last": "Chang", "suffix": ""}, {"first": "C.-J", "middle": [], "last": "Kuo", "suffix": ""}, {"first": "S.-S", "middle": [], "last": "Lee", "suffix": ""}, {"first": "C.-C", "middle": [], "last": "Hou", "suffix": ""}, {"first": "P.-W", "middle": [], "last": "Hsiao", "suffix": ""}, {"first": "S.-C", "middle": [], "last": "Chien", "suffix": ""}, {"first": "L.-F", "middle": [], "last": "Shyur", "suffix": ""}, {"first": "N.-S", "middle": [], "last": "Yang", "suffix": ""}], "year": 2007, "venue": "J. Med. Chem", "volume": "50", "issn": "", "pages": "4087--4095", "other_ids": {}}, "BIBREF95": {"ref_id": "b95", "title": "Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication", "authors": [{"first": "C.-C", "middle": [], "last": "Wen", "suffix": ""}, {"first": "L.-F", "middle": [], "last": "Shyur", "suffix": ""}, {"first": "J.-T", "middle": [], "last": "Jan", "suffix": ""}, {"first": "P.-H", "middle": [], "last": "Liang", "suffix": ""}, {"first": "C.-J", "middle": [], "last": "Kuo", "suffix": ""}, {"first": "P", "middle": [], "last": "Arulselvan", "suffix": ""}, {"first": "J.-B", "middle": [], "last": "Wu", "suffix": ""}, {"first": "S.-C", "middle": [], "last": "Kuo", "suffix": ""}, {"first": "N.-S", "middle": [], "last": "Yang", "suffix": ""}], "year": 2011, "venue": "J. Tradit. Complement. Med", "volume": "1", "issn": "", "pages": "41--50", "other_ids": {}}, "BIBREF96": {"ref_id": "b96", "title": "Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia", "authors": [{"first": "P", "middle": ["C Y"], "last": "Woo", "suffix": ""}, {"first": "S", "middle": ["K P"], "last": "Lau", "suffix": ""}, {"first": "C", "middle": [], "last": "Chu", "suffix": ""}, {"first": "K", "middle": [], "last": "Chan", "suffix": ""}, {"first": "H", "middle": [], "last": "Tsoi", "suffix": ""}, {"first": "Y", "middle": [], "last": "Huang", "suffix": ""}, {"first": "B", "middle": ["H L"], "last": "Wong", "suffix": ""}, {"first": "R", "middle": ["W S"], "last": "Poon", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Cai", "suffix": ""}, {"first": "W", "middle": [], "last": "Luk", "suffix": ""}], "year": 2005, "venue": "J. Virol", "volume": "79", "issn": "", "pages": "884--895", "other_ids": {}}, "BIBREF97": {"ref_id": "b97", "title": "World Health Organization, 2020a. Coronavirus disease (COVID-19): Situation Report -176", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF98": {"ref_id": "b98", "title": "Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). World Health Organization", "authors": [], "year": 2003, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF100": {"ref_id": "b100", "title": "Traditional Chinese medicine formula for treating or preventing novel coronavirus pneumonia and viral influenza", "authors": [{"first": "Tongwu", "middle": [";"], "last": "Wu", "suffix": ""}, {"first": "Li", "middle": [";"], "last": "Liang", "suffix": ""}, {"first": "", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Tangjiang; Liang", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF101": {"ref_id": "b101", "title": "Preparative isolation and purification of celastrol from Celastrus orbiculatus Thunb. by a new counter-current chromatography method with an upright coil planet centrifuge", "authors": [{"first": "S", "middle": [], "last": "Wu", "suffix": ""}, {"first": "C", "middle": [], "last": "Sun", "suffix": ""}, {"first": "K", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Pan", "suffix": ""}], "year": 2004, "venue": "J. Chromatogr. A", "volume": "1028", "issn": "", "pages": "171--174", "other_ids": {}}, "BIBREF102": {"ref_id": "b102", "title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", "authors": [{"first": "Z", "middle": [], "last": "Wu", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Mcgoogan", "suffix": ""}], "year": 2020, "venue": "JAMA", "volume": "323", "issn": "", "pages": "1239--1242", "other_ids": {}}, "BIBREF104": {"ref_id": "b104", "title": "Epidemic prevention traditional Chinese medicine composition and preparation method and application thereof", "authors": [{"first": "Yue;", "middle": [], "last": "Wang", "suffix": ""}, {"first": "", "middle": [], "last": "Shi", "suffix": ""}, {"first": ";", "middle": [], "last": "Suofang", "suffix": ""}, {"first": "", "middle": [], "last": "Qiao", "suffix": ""}, {"first": ";", "middle": [], "last": "Fei", "suffix": ""}, {"first": "", "middle": [], "last": "Wu", "suffix": ""}, {"first": ";", "middle": [], "last": "Lei", "suffix": ""}, {"first": "X", "middle": [], "last": "Wu", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF105": {"ref_id": "b105", "title": "Potential anti-angiogenic sulfates of andrographolide", "authors": [{"first": "X.-W", "middle": [], "last": "Xiao", "suffix": ""}, {"first": "H.-Z", "middle": [], "last": "Fu", "suffix": ""}, {"first": "Y.-H", "middle": [], "last": "Luo", "suffix": ""}, {"first": "X.-Y", "middle": [], "last": "Wei", "suffix": ""}], "year": 2013, "venue": "J. Asian Nat. Prod. Res", "volume": "15", "issn": "", "pages": "809--818", "other_ids": {}}, "BIBREF106": {"ref_id": "b106", "title": "Fumigation bath preparation for preventing and treating plague and use method and application thereof", "authors": [{"first": "Hanmei;", "middle": [], "last": "Yang", "suffix": ""}, {"first": "", "middle": [], "last": "Chen", "suffix": ""}, {"first": ";", "middle": [], "last": "Caihong", "suffix": ""}, {"first": "", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Yang", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF107": {"ref_id": "b107", "title": "Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus", "authors": [{"first": "C.-W", "middle": [], "last": "Yang", "suffix": ""}, {"first": "Y.-Z", "middle": [], "last": "Lee", "suffix": ""}, {"first": "I.-J", "middle": [], "last": "Kang", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Barnard", "suffix": ""}, {"first": "J.-T", "middle": [], "last": "Jan", "suffix": ""}, {"first": "D", "middle": [], "last": "Lin", "suffix": ""}, {"first": "C.-W", "middle": [], "last": "Huang", "suffix": ""}, {"first": "T.-K", "middle": [], "last": "Yeh", "suffix": ""}, {"first": "Y.-S", "middle": [], "last": "Chao", "suffix": ""}, {"first": "S.-J", "middle": [], "last": "Lee", "suffix": ""}], "year": 2010, "venue": "Antiviral Res", "volume": "88", "issn": "", "pages": "160--168", "other_ids": {}}, "BIBREF108": {"ref_id": "b108", "title": "Oligomycins A and C, major secondary metabolites isolated from the newly isolated strain Streptomyces diastaticus", "authors": [{"first": "P", "middle": ["W"], "last": "Yang", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Li", "suffix": ""}, {"first": "J", "middle": ["Y"], "last": "Zhao", "suffix": ""}, {"first": "M", "middle": ["Z"], "last": "Zhu", "suffix": ""}, {"first": "H", "middle": [], "last": "Shang", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Li", "suffix": ""}, {"first": "X", "middle": ["L"], "last": "Cui", "suffix": ""}, {"first": "R", "middle": [], "last": "Huang", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Wen", "suffix": ""}], "year": 2010, "venue": "Folia Microbiol. (Praha)", "volume": "55", "issn": "", "pages": "10--16", "other_ids": {}}, "BIBREF109": {"ref_id": "b109", "title": "Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective", "authors": [{"first": "Y", "middle": [], "last": "Yang", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Islam", "suffix": ""}, {"first": "J", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Li", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}], "year": 2020, "venue": "Int J Biol Sci", "volume": "16", "issn": "", "pages": "1708--1717", "other_ids": {}}, "BIBREF111": {"ref_id": "b111", "title": "Zoonotic origins of human coronaviruses", "authors": [{"first": "Z.-W", "middle": [], "last": "Ye", "suffix": ""}, {"first": "S", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "K.-S", "middle": [], "last": "Yuen", "suffix": ""}, {"first": "S.-Y", "middle": [], "last": "Fung", "suffix": ""}, {"first": "C.-P", "middle": [], "last": "Chan", "suffix": ""}, {"first": "D.-Y", "middle": [], "last": "Jin", "suffix": ""}], "year": 2020, "venue": "Int J Biol Sci", "volume": "16", "issn": "", "pages": "1686--1697", "other_ids": {}}, "BIBREF112": {"ref_id": "b112", "title": "Human aminopeptidase N is a receptor for human coronavirus 229E", "authors": [{"first": "C", "middle": ["L"], "last": "Yeager", "suffix": ""}, {"first": "R", "middle": ["A"], "last": "Ashmun", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "Williams", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Cardellichio", "suffix": ""}, {"first": "L", "middle": ["H"], "last": "Shapiro", "suffix": ""}, {"first": "A", "middle": ["T"], "last": "Look", "suffix": ""}, {"first": "K", "middle": ["V"], "last": "Holmes", "suffix": ""}], "year": 1992, "venue": "Nature", "volume": "357", "issn": "", "pages": "420--422", "other_ids": {}}, "BIBREF113": {"ref_id": "b113", "title": "Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells", "authors": [{"first": "L", "middle": [], "last": "Yi", "suffix": ""}, {"first": "Z", "middle": [], "last": "Li", "suffix": ""}, {"first": "K", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "X", "middle": [], "last": "Qu", "suffix": ""}, {"first": "J", "middle": [], "last": "Chen", "suffix": ""}, {"first": "G", "middle": [], "last": "Wang", "suffix": ""}, {"first": "H", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Luo", "suffix": ""}, {"first": "L", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "P", "middle": [], "last": "Jiang", "suffix": ""}, {"first": "L", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shen", "suffix": ""}, {"first": "M", "middle": [], "last": "Luo", "suffix": ""}, {"first": "G", "middle": [], "last": "Zuo", "suffix": ""}, {"first": "J", "middle": [], "last": "Hu", "suffix": ""}, {"first": "D", "middle": [], "last": "Duan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Nie", "suffix": ""}, {"first": "X", "middle": [], "last": "Shi", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Han", "suffix": ""}, {"first": "T", "middle": [], "last": "Li", "suffix": ""}, {"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "M", "middle": [], "last": "Ding", "suffix": ""}, {"first": "H", "middle": [], "last": "Deng", "suffix": ""}, {"first": "X", "middle": [], "last": "Xu", "suffix": ""}], "year": 2004, "venue": "J. Virol", "volume": "78", "issn": "", "pages": "11334--11339", "other_ids": {"DOI": ["10.1128/JVI.78.20.11334-11339"]}}, "BIBREF114": {"ref_id": "b114", "title": "Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains", "authors": [{"first": "Y", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "D", "middle": [], "last": "Cao", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "J", "middle": [], "last": "Ma", "suffix": ""}, {"first": "J", "middle": [], "last": "Qi", "suffix": ""}, {"first": "Q", "middle": [], "last": "Wang", "suffix": ""}, {"first": "G", "middle": [], "last": "Lu", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wu", "suffix": ""}, {"first": "J", "middle": [], "last": "Yan", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shi", "suffix": ""}], "year": 2017, "venue": "Nat. Commun", "volume": "8", "issn": "", "pages": "", "other_ids": {}}, "BIBREF115": {"ref_id": "b115", "title": "Traditional Chinese medicine composition with function of resisting novel coronavirus sars-cov-2 and preparation method and application thereof", "authors": [{"first": "Ning", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Yang", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF116": {"ref_id": "b116", "title": "Zhang Tangjiang and Liang Honghai 30 parts of dried ginger, 30-60 parts of honey-fried licorice root, 15-30 parts of American ginseng, 10-30 parts of Ephedra, 15-30 parts of Cassia twig, 5-10 parts of Asarum, 10-70 parts of honeysuckle flower, 10-30 parts of Fructus Forsythiae, 10-30 parts of Isatis root, 10-30 parts of reed rhizome, 15-30 parts of Folium Isatidis, 20-240 parts of Gypsum, 10-30 parts of lalang grass rhizome, 10-15 parts of Rhizoma Paridis, 5-15 parts of wrinkled Gianthyssop herb", "authors": [{"first": "\u5434\u901a\u6b66", "middle": [], "last": "Mhv-A59 Of Ephedra ; Rhizoma", "suffix": ""}, {"first": "\u6881\u529b", "middle": [], "last": "", "suffix": ""}, {"first": "\u5f20\u5802", "middle": [], "last": "English Name: Wu", "suffix": ""}, {"first": "Liang", "middle": [], "last": "Tongwu", "suffix": ""}, {"first": "", "middle": [], "last": "Li", "suffix": ""}], "year": null, "venue": "15-30 parts of Gypsum, 9 parts of Cassia Twig", "volume": "9", "issn": "", "pages": "", "other_ids": {}}, "BIBREF119": {"ref_id": "b119", "title": "Chinese name: \u9648\u6587\u624d English name: Chen Wencai 20-100 g of Laggera pterodonta, 10-50 g of honeysuckle, 10-30 g of dried ginger, 10-40 g of divaricate saposhnikovia root, 10-50 g of Officinal magnolia bark and 10-60 g resisting virus and enhancing immunity", "authors": [{"first": "Yang", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Chen et al., 2020 on confirmed pregnant women cases, demonstrated no evidence of trans-placental transmission. These women underwent cesarean sections, so the transmission by vaginal birth is still under debate (H. Chen et al., 2020). In the previous years, SARS-CoV (2003) infected about 8098 individuals in 26 regions around the world with a mortality rate of 9% (World Health Organization, 2003).", "latex": null, "type": "figure"}, "FIGREF1": {"text": "reported to inhibit entry and replication of many coronaviruses; SARS, MERS, etc... (in vitro and in vivo) (Tables 1 and 2; Fig. 4-6)", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Li and his co-authors tested around 200 Chinese medicinal plants against Severe Acute Respiratory Syndrome associated coronavirus (SARS-CoV) using MTS assay. The results demonstrated that 4 of the 200 plants extracts, namely L. radiata (L'H\u00e9r.), A. annua L., P. lingua Mirb. and L. aggregate Sims, showed superior activity at EC 50 of 2.4, 34.5, 43.2 and 88.2 \u00b5g/mL respectively compared with interferon alpha as a positive control (EC 50 = 660.3 IU/mL). Four potent extracts recorded CC 50 values ranged between 886.6\u00b135.0 to 2378.0\u00b187.3 \u00b5g/mL. CC 50 was determined based on reducing cell viability by using different concentration of extracts. As L. radiata (L'H\u00e9r.) was the most active one, it was subjected to fractionation and purification to find the most active compound, identified as lycorine (45). Lycorine is an alkaloid compound that gave EC 50 of 15.7 nM and CC 50 value of 14980.0 nM against SARS-CoV (Li et al., 2005). Lycorine have been investigated later against the other types of coronaviruses, HCoV-OC43, HCoV-NL63, MERS-CoV and MHV-A59 to give EC 50 values ranging from 0.15 \u00b5M to 1.63 \u00b5M (Shen et al., 2019). Emetine is a natural plant alkaloid of ipecac (Carapichea ipecacuanha L.), emetine dihydrochloride (31), a derivative of emetine inhibiting the viral protein synthesis of coronaviruses, with an EC 50 value of 0.12 to 1.43 \u00b5M. Emetine hydrochloride revealed the strongest anti-CoV activities against MERS-CoV and SARS-CoV with the lowest EC 50 of 0.014 and 0.05 \u00b5M), whilst the activity against HCoV-NL63, HCoV-OC43, MERS-CoV and MHV-A59 showed EC 50 values of 1.43 \u00b5M, 0.30, 0.34 and 0.12 \u00b5M respectively via blocking of viral propagation at an early stage of infection, thereby minimizing the chance of the virus to adapt and acquire drug resistance. It also has CC 50 values of 3.63, 2.69, 3.08 and 3.51 \u00b5M respectively (Dyall et al., 2017; Shen et al., 2019).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Thunb. family (Celastraceae), a Chinese herbal plant, traditionally used in the treatment of fever, chills, edema and bacterial infection (Wu et al., 2004), showed significant effect via inhibition of the 3CL pro enzyme. Three different extracts (EtOH, EtOAc and water fraction) have been tested against SARS-CoV infection, and exhibited IC 50 values of 19.4, 17.8 and 38.7\u03bcg/ml respectively (Kumar et al., 2013). Similarly, hydroethanolic extraction of Echinacea purpurea plant roots showed potent activity against HCoV-229E, SARS-CoV and MERS-CoV with IC 50 values of 3.2, 50 and 50 \u00b5g/ml respectively (Signer et al., 2020). Furthermore, the essential oils of many plants play an important role against viral diseases i.e. Laurus nobilis, Juniperus oxycedrus ssp. oxycedrus, Thuja orientalis, Cupressus sempervirens ssp. pyramidalis, Pistacia palaestina, Salvia officinalis, and Satureja thymbra. The essential oils were investigated against SARS-CoV and HSV-1 viruses. The potent activity of L. nobilis oil was reported against SARS-CoV with IC 50 value of 120 \u00b5g/mL. The plant oil is characterized by the excitation of \u03b2-ocimene, 1,8cineole, \u03b1-pinene, and \u03b2-pinene as the principle constituents. These plants act via the inhibition of viral replication(Loizzo et al., 2008).", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Streptomyces spp. compounds including monensin sodium (73), cycloheximide (72), oligomycins (77), valinomycin (76), and antimycin A (71) were isolated and investigated in opposition to SARS-CoV-2. Monensin sodium is an antibacterial salt isolated from", "latex": null, "type": "figure"}, "FIGREF5": {"text": "a long time, natural products and their molecular frameworks constitute valuable starting points or sources for drug discovery (El-Seedi et al., 2019; Rodrigues et al., 2016). In line with Newman and Cragg, the number of antiviral drugs approved by the FDA in the period between 1981 to 2019 are 186 drugs, among them 87 are vaccines like FluMist \u00ae , Invivac \u00ae , Bilive \u00ae , Anflu \u00ae , Afluria \u00ae and Optaflu \u00ae , and are used against the influenza virus, 26 are synthetic but the pharmacophores are natural products, 17 are biological sources like peptides and proteins and 6 are natural products derivatives such as Tamiflu \u00ae , zanamivir \u00ae and virreal \u00ae , 21 are synthetic drugs (NP pharmacophore)/ mimics of natural products and other19 compounds are synthetics (Newman and Cragg, 2020).", "latex": null, "type": "figure"}, "FIGREF6": {"text": "was used in the current study as an effective agent against COVID-19 acting via an immunology modulation of phingosine-1-phosphate receptors (ClinicalTrials.gov; NCT04280588) (Driggin et al., 2020). Tetrandrine (58) represents the predominant constituent of the Stephania tetrandra plant, a Chinese traditional medicinal plant. Tetrandrine is bisbenzylisoquinoline alkaloid and recommended in the Chinese Pharmacopoeia as an analgesic and diuretic agent and also for treatment of hypertension and various other ailments like asthma, tuberculosis, dysentery, hyperglycemia, malaria, cancer and fever. It was also used against the Ebola virus infection (Bhagya and Chandrashekar, 2016). In the clinical studies, tetrandrine has been proven effective against COVID-19 via reducing the clinical progress, improving the prognosis, reducing the incidence of pulmonary fibrosis during rehabilitation, and improving patients' quality of life (ClinicalTrials.gov; NCT04308317). Tetrandrine has shown potential in decreasing the entry of SARS-CoV-2 S pseudovirions (Ou et al., 2020). Tocilizumab (82), is a humanized monoclonal antibody that interacts with the interleukin-6 receptor (IL-6R) and is nowadays approved by China's National Health", "latex": null, "type": "figure"}, "FIGREF7": {"text": "is a synthetic drug but its pharmacophore is a natural product origin (Quinin isolated from Cinchona spp. plant) (Oliveira et al., 2009), and approved antiphrastic (anti-malaria) drug as per the FDA (Newman and Cragg, 2020). In the 1960's, it was investigated as an antiviral in vitro for the first time (Touret and de Lamballerie, 2020). Chloroquine was able to inhibit MERS-CoV replication at a very early stage of infection with EC 50 of 3.0 \u00b5M, and it was reported as a potent anti-viral agent against flavivirus, influenza virus, HIV, Ebola virus, and Nipha-Hendravirus", "latex": null, "type": "figure"}, "FIGREF8": {"text": "Gianthyssop herb. The effective rate of treatment was reported to 95%. The percent of effective rates was calculated based on the number of confirmed diagnosis and the number of treated patients from different places. This patent was documented in patent office CN with publication number (CN110870402A)(Ge, 2020).Another TCM prescription is composed of the following raw materials in parts byweight: 40 parts of Folium isatidis, 40 parts of the wild Chrysanthemum flower, 20 parts of Coptis chinensis, 30 parts of sweetsop seed, 20 parts of wrinkled Gianthyssop herb, 20 parts of Rhizoma Atractylodis, 20 parts of Radix Bupleuri, 2 parts of Calculus Bovis Factitius, 20 parts of Houttuynia cordata, 5 parts of dandelion root, 30 parts of honeysuckle, 30 parts of Fructus Forsythiae, 20 parts of Scutellaria baicalensis, 20 parts of blackberry lily, 15 parts of Salvia miltiorrhiza, 15 parts of Bulbus Fritillariae Cirrhosae, 10 parts of Saussurea involucrate, 60 parts of Astragalus mongholicus, 20 parts of Cordyceps sinensis, 20 parts of Codonopsis. Observation of clinical experiments shows that the patent boosted the pneumonia symptoms caused by the new SARS-Cov-2 coronavirus. This patent was documented in patent office CN with publication number (CN111150792A)(Zhang, Ning., Yang, 2020).Tripterygium wilfordii is the main formula for one of the TCM patents. The composition of this patent has the following raw materials as parts by weight: 3-15 parts of Tripterygium wilfordii, 10-50 parts of Gypsum, 8-24 parts of raw Chinese yam, 5-15 parts of Radix Scrophulariae, 4-12 parts of Fructus Forsythiae, 4-10 parts of Periostracum cicada, 4-12 parts of Codonopsis pilosula, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre. This patent was claimed suitable for the severe stage of COVID-19 pneumonia diseases, regulating immunity and decreasing the fever.The administration rate of the prescription (3-5 times) can decrease body temperature to the normal range. Tripterygium wilfordii relates to Chinese herbal medicine, and used in traditional medicine for promoting blood circulation, killing parasites, regulating immunity, and has a good medicinal effect when utilized in treating 2019 new coronavirus pneumonia. This patent was documented in patent office CN with publication number (CN111184805A) (Lei, Ming; Yang, 2020).One more patent that also relates to TCM, is possessing a formula for treating or preventing both novel coronavirus pneumonia and viral influenza. This formula combinesraw materials, parts by weight, as a following: 15-45 parts of prepared aconite, 10-30 parts of dried ginger, 30-60 parts of honey-fried licorice root, 15-30 parts of American ginseng, 10-30 parts of Ephedra, 15-30 parts of Cassia twig, 5-10 parts of Asarum, 10-70 parts of honeysuckle flower, 10-30 parts of Fructus Forsythiae, 10-30 parts of Isatis root, 10-30 parts of reed rhizome, 15-30 parts of Folium Isatidis, 20-240 parts of Gypsum, 10-30 parts of lalang grass rhizome, 10-15 parts of Rhizoma Paridis, 5-15 parts of wrinkled Gianthyssop herb, 5-10 parts of Eupatorium, 5-10 parts of safflower, 5-15 parts of Cortex Moutan, 5-15 parts of Rheum officinale, 15-45 parts of ginger, 10-30 parts of Chinese date and 5-9 parts of musk. This patent has a corollary effect on ventilating lungs and improving human immunity. It was used for coronavirus, influenza, and pneumonia prevention or treatment. The findings showed that 24 patients out of 30 were cured and that this formula was helpful in treating the new coronavirus pneumonia effectively. The cure rate was estimated to 80%. This patent was documented in patent office was studied in vitro against common coronavirus and new coronavirus. The formula composed of the following raw materials, as parts by weight: 40 parts of wrinkled Gianthyssop herb, 40 parts of wild Chrysanthemum flower, 24 parts of Chinese mosla herb and 40 parts of sweet wormwood herb. This formula has a potent effect on inhibiting cytokine expression i.e. TNF-\u03b1 and IL-6 produced by SARS-Cov-2.The formula was used earlier as a therapeutic agent against pneumonia, nephritis, hepatitis. It has very good prospects for clinical application and thus it was approved from CN patent office under publication number (CN111150755A)(Pan, Yaozong.,   Wang, Hengbin., Zhang, Dandan., Zhang, Bangguo., Li, Quan., Luo, Niancui., Cao,   Zeqing., Zhai, 2020).", "latex": null, "type": "figure"}, "FIGREF9": {"text": "This work was supported by the Swedish Research Council Vetenskapsr\u00e5det (grants 2015-05468 and 2016-05885) in patients infected with group A hemolytic streptococci: a comparison with serum antistreptolysin and gamma globulin levels with special reference to the occurrence of rheumatic fever. J. Clin. Invest. 27, 425-434. Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A., Al-Rabiah, F.A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W.N., Balkhy, H.H., Al-Hakeem, R.F., Makhdoom, H.Q., Zumla, A.I., Memish, Z.A., 2013. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752-761. Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L., Wang, M., 2020. Presumed asymptomatic carrier transmission of COVID-19. JAMA 323, 1406-1407. Basiri, M.R., 2020. Theory about Treatments and Morbidity Prevention of Corona Virus Disease (Covid-19). J. Pharm. Pharmacol. 8, 89-90. Bassetti, M., Vena, A., Giacobbe, D.R., 2020. The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm. Eur. J. Clin. Invest. 50, e13209. Bhagya, N., Chandrashekar, K.R., 2016. Tetrandrine-A molecule of wide bioactivity. Phytochemistry 125, 5-13. Bitnun, A., Allen, U., Heurter, H., King, S.M., Opavsky, M.A., Ford-Jones, E.L., Matlow, A., Kitai, I., Tellier, R., Richardson, S., Manson, D., Babyn, P., Read, S., 2003. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics 112, e261-e261. Bittencourt, V.R.E.P., Mascarenhas, A.G., de Menezes, G.C.R., Monteiro, S.G., 2000. In vitro action of Metarhizium anisopliae (Metschnikoff, 1879) Sorokin, 1883 and Beauveria bassiana (Balsamo) Vuillemin, 1912 on eggs of the tick Anocentor nitens (Neummann, 1897)(Acari: Ixodidae). Rev. Bras. Med. Veterin\u00e1ria 22, 248-251. Calder, P.C., Carr, A.C., Gombart, A.F., Eggersdorfer, M., 2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients 12, 1181. Chan-Yeung, M., Xu, R.H., 2003. SARS: epidemiology. Respirology 8, S9-S14. Chan, J.F.-W., Yuan, S., Kok, K.-H., To, K.K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C.C.-Y., Poon, R.W.-S., Chan, W.-M., Daniel, J., Cai, J.-P., Cheng, V.C.-C., Chen, H., Hui, C.K.-M., Yuen, K.-Y., 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514-523. Chan, P.K.S., Chan, M.C.W., 2013. Tracing the SARS-coronavirus. J. Thorac. Dis. 5, S118-S121. Chen, C.-J., Michaelis, M., Hsu, H.-K., Tsai, C.-C., Yang, K.D., Wu, Y.-C., Cinatl, J., Doerr, H.W., 2008. Toona sinensis Roem tender leaf extract inhibits doi.org/https://doi.org/10.1016/j.jep.2008.07.048 Chen, F., Chan, K.H., Jiang, Y., Kao, R.Y.T., Lu, H.T., Fan, K.W., Cheng, V.C.C., Tsui, W.H.W., Hung, I.F.N., Lee, T.S.W., Guan, Y., Peiris, J.S.., Yuen, K.., 2004. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 31, 69-75. Chen, H., Guo, J., Wang, C., Luo, F., Yu, X., Zhang, W., Li, J., Zhao, D., Xu, D., Gong, Q., Liao, J., Yang, H., Hou, W., Zhang, Y., 2020. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 395, 809-815. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., Zhang, L., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, //doi.org/https://doi.org/10.1016/S0140-6736(20)30211-7 Chen, W., 2020. Laggera pterodonta composition for treating covid-19 and application thereof. CN111166862A. Cheng, P.-W., Ng, L.-T., Chiang, L.-C., Lin, C.-C., 2006. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin. Exp. Pharmacol. Physiol. 33, 612-616. https://doi.org/10.1111/j.1440-1681.2006.04415.x Cheng, Y., 2006. Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141. ChemBioChem 7, 471-477. Chhikara, B.S., Rathi, B., Singh, J., Poonam, F.N.U., 2020. Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective 406. Donia, M., Hamann, M.T., 2003. Marine natural products and their potential applications as anti-infective agents. Lancet Infect. Dis. 3, 338-348. Driggin, E., Madhavan, M. V, Bikdeli, B., Chuich, T., Laracy, J., Bondi-Zoccai, G., Brown, T.S., Der Nigoghossian, C., Zidar, D.A., Haythe, J., Brodie, D., Beckman, J.A., Kirtane, A.J., Stone, G.W., Krumholz, H.M., Parikh, S.A., 2020. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J. Am. Coll. Cardiol. 75, 2352 -2371. Dua, V.K., Verma, G., Singh, B., Rajan, A., Bagai, U., Agarwal, D.D., Gupta, N.C., Kumar, S., Rastogi, A., 2013. Anti-malarial property of steroidal alkaloid conessine isolated from the bark of Holarrhena antidysenterica. Malar. J. 12, 194. Dyall, J., Gross, R., Kindrachuk, J., Johnson, R.F., Olinger, G.G., Hensley, L.E., Frieman, M.B., Jahrling, P.B., 2017. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs 77, 1935-1966. https://doi.org/10.1007/s40265-017-0830-1. El-Seedi, H.R., Khalifa, S.A.M., Yosri, N., Khatib, A., Chen, L., Saeed, A., Efferth, T., Verpoorte, R., 2019. Plants mentioned in the Islamic Scriptures (Holy Qur'\u00e2n and Ahadith): Traditional uses and medicinal importance in contemporary times. J. Ethnopharmacol. 243, 112007. Elfiky, A.A., Mahdy, S.M., Elshemey, W.M., 2017. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J. Med. Virol. 89, 1040-1047. Feinberg, S.M., Feinberg, A.R., Pruzansky, J., Fisherman, E.W., 1957. Methylprednisolone (medrol), a potent new anti-inflammatory steroid: Therapeutic results in allergic diseases. J. Am. Med. Assoc. 165, 1560-1562. Fielding, B.C., 2011. Human coronavirus NL63: a clinically important virus? Future Microbiol. 6, 153-159. Fowler, R.A., Lapinsky, S.E., Hallett, D., Detsky, A.S., Sibbald, W.J., Slutsky, A.S., Stewart, T.E., 2003. Critically ill patients with severe acute respiratory syndrome. Jama 290, 367-373. dependent protein kinase II. Mol. Cancer Ther. 12, 2067-2077. Moloudizargari, M., Mikaili, P., Aghajanshakeri, S., Asghari, M.H., Shayegh, J., 2013. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn. Rev. 7, 199-212. Newman, D.J., Cragg, G.M., 2020. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 83, 770-803. Ng, D.L., Al Hosani, F., Keating, M.K., Gerber, S.I., Jones, T.L., Metcalfe, M.G., Tong, S., Tao, Y., Alami, N.N., Haynes, L.M., Mutei, M.A., Abdel-Wareth, L., Uyeki, T.M., Swerdlow, D.L., Barakat, M., Zaki, S.R., 2016. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am. J. Pathol. 186, 652-658. Niemann, H., Boschek, B., Evans, D., Rosing, M., Tamura, T., Klenk, H.D., 1982. Posttranslational glycosylation of coronavirus glycoprotein E1: inhibition by monensin. EMBO J. 1, 1499-1504. Oh, M.H., Houghton, P.J., Whang, W.K., Cho, J.H., 2004. Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine 11, 544-548. Oliveira, A.B., Dolabela, M.F., Braga, F.C., J\u00e1come, R.L.R.P., Varotti, F.P., P\u00f3voa, M.M., 2009. Plant-derived antimalarial agents: new leads and efficient phythomedicines. Part I. Alkaloids. An. Acad. Bras. Cienc. 81, 715-740. Orlikova, B., Tasdemir, D., Golais, F., Dicato, M., Diederich, M., 2011. The aromatic ketone 4'-hydroxychalcone inhibits TNFalpha-induced NF-//doi.org/10.1016/j.bcp.2011.06.012", "latex": null, "type": "figure"}, "FIGREF10": {"text": ". Chinese medicine composition for Zhang, Taotao; He, Lihua; Peng, Y., 2020. Traditional chinese medicine composition and preparation method and pharmaceutical application thereof. CN111214637A. Zhang, L., Koyyalamudi, S.R., Jeong, S.C., Reddy, N., Bailey, T., Longvah, T., 2013. Immunomodulatory activities of polysaccharides isolated from Taxillus chinensis and Uncaria rhyncophylla. Carbohydr. Polym. 98, 1458-1465. Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.", "latex": null, "type": "figure"}, "FIGREF11": {"text": "Different types of coronavirus (CoVs) and their pathogenesis Illustrating the structure of SARS-CoV-2 (COVID-19).", "latex": null, "type": "figure"}, "FIGREF12": {"text": "Mechanism of SARS-CoV-2 replication Structures of isolated anti-viral compounds of plant origin and their derivatives Structures of isolated anti-viral compounds of marine origin or their derivatives Fig. 6. Structures of isolated anti-viral compounds of microbial origin or their derivatives Structures of isolated compounds and their derivatives from natural products sources in clinical trial studies against COVID-19", "latex": null, "type": "figure"}, "TABREF1": {"text": "List of isolated anti-viral natural products compounds and their derivatives", "latex": null, "type": "table", "html": "<html><body><table><tr><td>(N), flavonoid (13) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>7\u03b2 -\n</td><td>C. japonica </td><td>Inhibits viral replication </td><td>SARS-CoV </td><td>1.15 (127) \u00b5M </td><td>(Wen et al., </td></tr><tr><td>hydroxydeoxycryptoja\nponol (N), diterpenoid (14) </td><td>L. </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>2007) </td></tr><tr><td>8 \u03b2-hydroxyabieta-\n</td><td>C. obtuse var. formosana </td><td>Inhibits viral replication </td><td>SARS-CoV </td><td>1.47 (&gt;750) </td><td>(Wen et al., </td></tr><tr><td>9(11),13-dien-12-one </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>2007) </td></tr><tr><td>(N), diterpenoid (15) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Acetyl-O-\nmethyltylophorinidine </td><td>T.indica L. </td><td>Inhibits viral replication </td><td>TGEV </td><td>403 \u00b1 22 </td><td>(Govindachar\n</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(&gt;100,000) </td><td>i et al., 1973; </td></tr><tr><td>(ND), alkaloid (16) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>nM </td><td>C.-W. Yang </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>et al., 2010) </td></tr><tr><td>Aloeemodin (N), anthraquinone (17) </td><td>Isatis indigotica </td><td>Inhibits enzymatic activity of virus </td><td>SARS-CoV </td><td>366 (11592) \u00b5M </td><td>(Lin et al., 2005) </td></tr><tr><td>Baicalin (N), flavonoid </td><td>Scutellaria baicalensis </td><td>Inhibits the enzymatic activity </td><td>SARS-CoV </td><td>12.5-25 </td><td>(Chen et al., </td></tr><tr><td>(18) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td> (&gt;100) \u00b5g/ml </td><td>2004; Deng et al., 2012) </td></tr><tr><td>Berbamine (N), bis-\nbenzylisoquinoline </td><td>Berberis amurensis </td><td>Inhibits viral replication </td><td>HCoV-OC43 </td><td>1.48 (&gt;20) \u00b5M </td><td>(Meng et al., </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>HCoV-NL63 </td><td>9.46 (&gt;20) \u00b5M </td><td>2013; Shen et </td></tr><tr><td>alkaloids (19) </td><td>\u00a0</td><td>\u00a0</td><td>MERS-CoV </td><td>13.14 (&gt;20) \u00b5M </td><td>al., 2019) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MHV-A59 </td><td>10.91 (&gt;20) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>\u00a0</td></tr><tr><td>Beta-sitosterol (N), </td><td>I. indigotica </td><td>Inhibits enzymatic activity of virus </td><td>SARS-CoV </td><td>1210 (1475) </td><td>(Lin et al., </td></tr><tr><td>steroid (20) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>2005) </td></tr><tr><td>Betulonic acid (N), </td><td>J. formosana </td><td>Inhibits viral replication </td><td>SARS-CoV </td><td>0.63 (112) \u00b5M </td><td>(Wen et al., </td></tr><tr><td>triterpene (21) </td><td>L. </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>2007) </td></tr><tr><td>Broussochalcone A </td><td>B. </td><td>Inhibits coronavirus proteases enzyme </td><td>MERS-CoV </td><td>42.1\u00b15.0 \u00b5M </td><td>(Park et al., </td></tr><tr><td>(N), polyphenol (22) </td><td>papyriferat </td><td>\u00a0</td><td>SARS-CoV </td><td>88.1\u00b113.0 \u00b5M </td><td>2017) </td></tr><tr><td>Broussochalcone B </td><td>Broussonetia papyrifera </td><td>Inhibits coronavirus proteases enzyme </td><td>MERS-CoV </td><td>112.9\u00b110.1 </td><td>(Park et al., </td></tr><tr><td>(N), polyphenol (23) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>2017) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>SARS-CoV </td><td>57.8\u00b10.5 \u00b5M </td><td>\u00a0</td></tr><tr><td>Broussoflavan A (N), </td><td>B. papyrifera </td><td>Inhibits coronavirus proteases enzyme </td><td>MERS-CoV </td><td>49.1\u00b17.5 \u00b5M </td><td>(Park et al., </td></tr><tr><td>flavonoid (24) </td><td>\u00a0</td><td>\u00a0</td><td>SARS-CoV </td><td>92.4\u00b12.1 \u00b5M </td><td>2017) </td></tr><tr><td>Cedrane-3 \u03b2,12-diol </td><td>J. formosana </td><td>Inhibits viral replication </td><td>SARS-CoV </td><td>&gt;10 (&gt;750) </td><td>(Wen et al., </td></tr><tr><td>(N), sesquiterpenoid (25) </td><td>L. </td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>2007) </td></tr><tr><td>Cepharanthine, (N), </td><td>S. tetrandra </td><td>Inhibits viral S and N protein expression/ </td><td>HCoV-229E </td><td>729.7 nM </td><td>(Kim et al., </td></tr><tr><td>(bis-\n</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>2019) </td></tr><tr><td>benzylisoquinoline </td><td>\u00a0</td><td>Suppressed the replication </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>alkaloids) (26) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chloroquine (S*), </td><td>Cinchona </td><td>Inhibits viral replication </td><td>HCoV-OC43 </td><td>0.33 (&gt;20) \u00b5M </td><td>(Keyaerts et </td></tr><tr><td>alkaloid (27) </td><td>spp. </td><td>\u00a0</td><td>HCoV-NL63 </td><td>4.89 (&gt;20) \u00b5M </td><td>al., 2009; </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MERS-CoV </td><td>16.44 (&gt;20) </td><td>Oliveira et </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>al., 2009; </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MHV-A59 </td><td>15.92 (&gt;20) </td><td>Shen et al., </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>2019) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>SARS-CoV </td><td>8.8\u00b11.2 \u00b5M </td><td>\u00a0</td></tr><tr><td>Conessine (N), steroid </td><td>Holarrhena antidysenteri\n</td><td>Inhibits viral replication </td><td>HCoV-OC43 </td><td>2.34 (&gt;20) \u00b5M </td><td>(Dua et al., </td></tr><tr><td>alkaloid (28) </td><td>HCoV-NL63 </td><td>10.75 (&gt;20) </td><td>2013; Shen et </td></tr><tr><td>ca </td><td>\u00a0</td><td>\u00a0</td><td>\u00b5M </td><td>al., 2019) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>MERS-CoV </td><td>4.98 (&gt;20) \u00b5M </td><td>\u00a0</td></tr></table></body></html>"}, "TABREF2": {"text": "List of patents on the treatment of COVID-19 by using Traditional Chinese", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Inventor </td><td>Ingredients (parts by weight)/ </td><td>Title/ Publication number/ </td><td>Type of virus/ Effective rate or (cure rate)/ Mode of action </td><td>References </td></tr><tr><td>Patent form </td><td>Patent office </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>9 parts of ephedra, 6 parts of honey-\n</td><td>Prescription for pneumonia caused coronavirus </td><td>treating by novel infection and </td><td>SARS-CoV-2/ </td><td>(Ge, 2020) </td></tr><tr><td>\u845b\u53c8\u6587 </td><td>fried licorice root, 9 parts of almond, </td><td>95.12%/ </td><td>\u00a0</td></tr><tr><td>English name: </td><td>15-30 parts of Gypsum, 9 parts of </td><td>\u00a0</td><td>Treating pneumonia </td><td>\u00a0</td></tr><tr><td>Ge Youwen </td><td>Cassia Twig, 9 parts of Rhizoma Alismatis, 9 parts of Grifola, 9 parts of bighead Atractylodes rhizome, 15 parts of Poria cocos, 16 parts of Radix Bupleuri, 6 parts of Scutellaria baicalensis, 9 parts of ginger processed Pinellia tuber, 9 </td><td>application thereof / (CN110870402A)/ CN </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>parts of ginger, 9 parts of aster, 9 parts of Flos Farae, 9 parts of blackberry lily, 6 parts of Asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled Gianthyssop herb/ </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>Decoction 40 parts of Folium Isatidis, 40 parts of the wild Chrysanthemum flower, </td><td>Traditional Chinese medicine composition with function of </td><td>SARS-CoV-2/ </td><td>(Zhang, </td></tr><tr><td>\u5f20\u5b81 and \u6768\u6d77\u519b </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Not reported/ </td><td>Ning., </td></tr><tr><td>English name: </td><td>20 parts of Coptis chinensis, 30 parts </td><td>resisting novel </td><td>coronavirus preparation application </td><td>Improve the pneumonia symptom </td><td>Yang, </td></tr><tr><td>Zhang Ning and </td><td>of sweetsop seed, 20 parts of </td><td>sars-cov-2 and method and thereof/ </td><td>\u00a0</td><td>2020) </td></tr><tr><td>Yang Haijun </td><td>wrinkled Gianthyssop herb, 20 parts of Rhizoma Atractylodis, 20 parts of Radix Bupleuri, 2 parts of Calculus </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Bovis Factitius, 20 parts of Houttuynia cordata, 5 parts of dandelion root, 30 parts of honeysuckle, 30 parts of Fructus Forsythiae, 20 parts of Scutellaria baicalensis, 20 parts of blackberry lily, 15 parts of Salvia miltiorrhiza, 15 parts of Bulbus Fritillariae </td><td>Bibliography There are no sources in the current document. (CN111150792A)/ CN </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>Cirrhosae, 10 parts of Saussurea involucrate, 60 parts of Astragalus mongholicus, 20 parts of Cordyceps sinensis, 20 parts of Codonopsis/ Tablet, capsule, granule, pill or oral liquid. 33-15 parts of Tripterygium </td><td>Traditional Chinese medicine </td><td>SARS-Cov-2/ </td><td>(Lei, Ming; </td></tr><tr><td>\u96f7\u9e23 and \u517b\u7acb </td><td>wilfordii, 10-50 parts of Gypsum, 8-\n24 parts of raw Chinese yam, 5-15 </td><td>thereof/ </td><td>composition and application (CN111184805A)/ </td><td>Not reported/ Regulating immunity and </td><td>Yang, 2020) </td></tr><tr><td>English name: Lei Ming and Yang Li </td><td>parts of Radix Scrophulariae, 4-12 parts of Fructus Forsythiae, 4-10 parts of Periostracum Cicada, 4-12 </td><td>CN </td><td>\u00a0</td><td>utilized to treating SARS-\nCov-2 </td><td>\u00a0</td></tr><tr><td>parts of Codonopsis pilosula, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre/ Not </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>reported 15-45 parts of prepared aconite, 10- </td><td>Traditional Chinese medicine </td><td>SARS-CoV-2/ </td><td>(Wu, </td></tr></table></body></html>"}, "TABREF3": {"text": "List of isolated anti-viral natural products compounds and their derivatives P. tomentosa (Thunb). Inhibits PLpro enzyme SARS-CoV 11.6\u00b10.13 \u00b5M (Cho et al., 2013) Tomentin D (N), coumarin (63) P. tomentosa (Thunb). Inhibits PLpro enzyme SARS-CoV 12.5\u00b10.22 \u00b5M (Cho et al., 2013) Tomentin E (N), coumarin (64) P. tomentosa (Thunb).", "latex": null, "type": "table"}, "TABREF4": {"text": "List of plants extracts used as anti-coronaviruses", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Plants </td><td>Type of extract </td><td>Organism/ Mechanism </td><td>IC50 or EC50 (CC50) value ug/mL </td><td>References </td></tr><tr><td>Artemisia annua L., </td><td>EtOH </td><td>SARS-CoV </td><td>34.5 (1053) </td><td>(Li et al., 2005) </td></tr><tr><td>Whole plant </td><td>\u00a0</td><td>Reduces RNA replication </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Cassia tora (CTH) </td><td>EtOH </td><td>SARS-CoV </td><td>\u00a0</td><td>(Wen et al., 2011) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits viral replication </td><td>8.43 (&gt;500) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits enzymatic activity </td><td>&gt;50 </td><td>\u00a0</td></tr><tr><td>Celastrus orbiculatus Thunb. </td><td>EtOH </td><td>SARS-CoV </td><td>19.4 </td><td>(Kumar et al., 2013) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>NR </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>EtOAc </td><td>SARS-CoV </td><td>17.8 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>NR </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>Aqueous </td><td>SARS-CoV </td><td>38.7 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>NR </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Cibotium barometz (CBE) </td><td>EtOH </td><td>SARS-CoV </td><td>\u00a0</td><td>(Wen et al., 2011) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits viral replication </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits enzymatic </td><td>8.42 (&gt;500) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>activity </td><td>&gt;50 </td><td>\u00a0</td></tr><tr><td>C. barometz (CBM) </td><td>EtOH </td><td>SARS-CoV </td><td>\u00a0</td><td>(Wen et al., </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>2011) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits viral replication </td><td>&gt;10 (&gt;500) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits enzymatic activity </td><td>39 </td><td>\u00a0</td></tr><tr><td>Dioscorea batatas (DBM) </td><td> EtOH </td><td>SARS-CoV </td><td>\u00a0</td><td>(Wen et al., 2011) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits viral replication </td><td>8.06 (&gt;500) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits enzymatic activity </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>44 </td><td>\u00a0</td></tr><tr><td>Echinacea purpurea, </td><td>Aqueous ethanol </td><td>SARS-CoV </td><td>50 </td><td>(Signer et al., </td></tr><tr><td>Roots </td><td>\u00a0</td><td>Inhibits viral replication </td><td>\u00a0</td><td>2020) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>MERS-CoV </td><td>50 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits viral replication </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>HCoV-229E </td><td>3.2 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits viral replication </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Gentiana scabra (GSH), </td><td>EtOH </td><td>SARS-CoV </td><td>\u00a0</td><td>(Wen et al., 2011) </td></tr><tr><td>Rhizomes </td><td>\u00a0</td><td>Inhibits viral replication </td><td>8.70 (&gt;500) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Inhibits enzymatic activity </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>&gt;50 </td><td>\u00a0</td></tr><tr><td>J. oxycredrus, </td><td>Essential oil </td><td>SARS-CoV </td><td>270 </td><td>(Loizzo et al., 2008) </td></tr><tr><td>Berries </td><td>\u00a0</td><td>Inhibits viral replication </td><td>\u00a0</td><td>\u00a0</td></tr></table></body></html>"}, "TABREF5": {"text": "List of ongoing clinical trials of natural products-based drugs targeting.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Compounds </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>References </td></tr><tr><td>\u00a0</td><td>Natural products origin </td><td>Clinical trials/phase/ Type of the study/ No of participants </td><td>Dose/ administration route/ Mechanism of action </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>(9-Dehydro-17-hydro-\n</td><td>\u00a0</td><td>2019 Novel </td><td>10-20 ml daily of </td><td>ClinicalTrials.govIdenti\nfier (https://clinicaltrials.gov, </td></tr><tr><td>andrographolide (DHA) </td><td>Andrographis paniculata, plant </td><td>Coronavirus </td><td>\u00a0</td><td>NCT04275388) </td></tr><tr><td>(78) and sodium 9-\n</td><td>\u00a0</td><td>Pneumonia/ </td><td>Xiyanping plus lopinavir tablet or ritonavir tablet plus \u03b1-interferon </td><td>\u00a0</td></tr><tr><td>dehydro-17-hydro-\n</td><td>\u00a0</td><td>Observational/ 426 </td><td>\u00a0</td></tr><tr><td>andrographolide-19-yl </td><td>\u00a0</td><td>P </td><td>nebulization, For 14 </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>days/ injection </td><td>\u00a0</td></tr><tr><td>sulfate (DHAS)) (ND), </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Xiyanping products (79) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chloroquine (S*), </td><td>Cinchona spp., </td><td>COVID19, </td><td>10 mg/kg followed </td><td>(https://clinicaltrials.gov, </td></tr><tr><td>alkaloid (27) </td><td>Plant </td><td>Coronavirus, Acute </td><td>by155 mg daily (250 </td><td>NCT04303507) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Respiratory </td><td>mg chloroquine phospha\nte salt or 200 mg of or </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Illnesses/ </td><td>hydroxychloroquine </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Interventional/ 40000 P </td><td>sulphate)/ for 3 m </td><td>(https://clinicaltrials.gov, </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>SARS-CoV, Severe </td><td>150 mg/ twice daily/ 10 </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Acute Respiratory </td><td>days </td><td>NCT04323527) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Syndrome (SARS) </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Pneumonia/ Phase </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>2/ Interventional / 440 P </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Fingolimod (ND), </td><td>Isaria sinclairii, </td><td>Coronavirus </td><td>0.5 mg/ once daily, for </td><td>(https://clinicaltrials.gov, </td></tr><tr><td>Alkaloid (80) </td><td>Fungus </td><td>Disease (COVID-\n</td><td>\u00a0</td><td>NCT04280588) </td></tr><tr><td>\u00a0</td><td>19)/ Phase 2/ </td><td>three consecutive days/ oral / Effective agent </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Interventional/ 30P </td><td>against COVID-19 via </td><td>\u00a0</td></tr><tr><td>Methylprednisolone </td><td>\u00a0</td><td>COVID-19, </td><td>an immunology modulation of </td><td>(https://clinicaltrials.gov, </td></tr><tr><td>\u00a0</td><td>phingosine-1-phosphate receptors 1mg/kg/day/for 7 days/ </td></tr><tr><td>(ND), Steroid (81) </td><td>Corynebacterium simplex, </td><td>Novel Coronavirus </td><td>intravenous </td><td>NCT04273321) </td></tr><tr><td>\u00a0</td><td>Bacteria </td><td>Pneumonia/ </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Interventional/ 86 P </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>COVID-19 </td><td>40 mg/ 12h for 5 days </td><td>(https://clinicaltrials.gov, </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Infections/ Phase 2/ </td><td>\u00a0</td><td>NCT04244591) </td></tr><tr><td>Tetrandrine (N), alkaloid </td><td>\u00a0</td><td>Interventional/ 80 P Corona Virus </td><td>60 mg QD for 1week </td><td>(https://clinicaltrials.gov, </td></tr><tr><td>(58) </td><td>Stephania tetrandra, Plant </td><td>Disease 2019,COVID-19/ Phase 4/ </td><td>\u00a0</td><td>NCT04308317) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>Interventional/ 60 P </td><td>\u00a0</td><td>\u00a0</td></tr></table></body></html>"}, "TABREF6": {"text": "List of patents on the treatment of COVID-19 by using Traditional Chinese Medicine", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Inventor </td><td>Ingredients (parts by weight)/ </td><td>Title/ Publication number/ </td><td>Type of virus/ Effective rate or (cure rate)/ Mode of action </td><td>References </td></tr><tr><td>Patent form </td><td>Patent office </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>9 parts of ephedra, 6 parts of honey-\n</td><td>Prescription for pneumonia caused coronavirus </td><td>treating by novel infection and </td><td>SARS-CoV-2/ </td><td>(Ge, 2020) </td></tr><tr><td>\u845b\u53c8\u6587 </td><td>fried licorice root, 9 parts of almond, </td><td>95.12%/ </td><td>\u00a0</td></tr><tr><td>English name: </td><td>15-30 parts of Gypsum, 9 parts of </td><td>\u00a0</td><td>Treating pneumonia </td><td>\u00a0</td></tr><tr><td>Ge Youwen </td><td>Cassia Twig, 9 parts of Rhizoma Alismatis, 9 parts of Grifola, 9 parts of bighead Atractylodes rhizome, 15 parts of Poria cocos, 16 parts of Radix Bupleuri, 6 parts of Scutellaria baicalensis, 9 parts of ginger processed Pinellia tuber, 9 </td><td>application thereof / (CN110870402A)/ CN </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>parts of ginger, 9 parts of aster, 9 parts of Flos Farae, 9 parts of blackberry lily, 6 parts of Asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled Gianthyssop herb/ </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>Decoction 40 parts of Folium Isatidis, 40 parts of the wild Chrysanthemum flower, </td><td>Traditional Chinese medicine composition with function of </td><td>SARS-CoV-2/ </td><td>(Zhang, </td></tr><tr><td>\u5f20\u5b81 and \u6768\u6d77\u519b </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>Not reported/ </td><td>Ning., </td></tr><tr><td>English name: </td><td>20 parts of Coptis chinensis, 30 parts </td><td>resisting novel </td><td>coronavirus preparation application </td><td>Improve the pneumonia symptom </td><td>Yang, </td></tr><tr><td>Zhang Ning and </td><td>of sweetsop seed, 20 parts of </td><td>sars-cov-2 and method and thereof/ </td><td>\u00a0</td><td>2020) </td></tr><tr><td>Yang Haijun </td><td>wrinkled Gianthyssop herb, 20 parts of Rhizoma Atractylodis, 20 parts of Radix Bupleuri, 2 parts of Calculus </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Bovis Factitius, 20 parts of Houttuynia cordata, 5 parts of dandelion root, 30 parts of honeysuckle, 30 parts of Fructus Forsythiae, 20 parts of Scutellaria baicalensis, 20 parts of blackberry lily, 15 parts of Salvia miltiorrhiza, 15 parts of Bulbus Fritillariae </td><td>Bibliography There are no sources in the current document. (CN111150792A)/ CN </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>Cirrhosae, 10 parts of Saussurea involucrate, 60 parts of Astragalus mongholicus, 20 parts of Cordyceps sinensis, 20 parts of Codonopsis/ Tablet, capsule, granule, pill or oral liquid. 33-15 parts of Tripterygium </td><td>Traditional Chinese medicine </td><td>SARS-Cov-2/ </td><td>(Lei, Ming; </td></tr><tr><td>\u96f7\u9e23 and \u517b\u7acb </td><td>wilfordii, 10-50 parts of Gypsum, 8-\n24 parts of raw Chinese yam, 5-15 </td><td>thereof/ </td><td>composition and application (CN111184805A)/ </td><td>Not reported/ Regulating immunity and </td><td>Yang, 2020) </td></tr><tr><td>English name: Lei Ming and Yang Li </td><td>parts of Radix Scrophulariae, 4-12 parts of Fructus Forsythiae, 4-10 parts of Periostracum Cicada, 4-12 </td><td>CN </td><td>\u00a0</td><td>utilized to treating SARS-\nCov-2 </td><td>\u00a0</td></tr><tr><td>parts of Codonopsis pilosula, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre/ Not </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Chinese name: </td><td>reported 15-45 parts of prepared aconite, 10- </td><td>Traditional Chinese medicine </td><td>SARS-CoV-2/ </td><td>(Wu, </td></tr></table></body></html>"}}, "back_matter": [{"text": "The authors declare no conflict of interest.", "cite_spans": [], "ref_spans": [], "section": "Conflicts of Interest:"}, {"text": "C. japonica L.Inhibits viral replication SARS-CoV 1.15 (127) \u00b5M (Wen et al., 2007) 8 \u03b2-hydroxyabieta-9(11),13-dien-12-one (N), diterpenoid ( ", "cite_spans": [{"start": 64, "end": 82, "text": "(Wen et al., 2007)", "ref_id": "BIBREF94"}], "ref_spans": [], "section": "annex"}, {"text": "Inhibits the enzymatic activity SARS-CoV 12.5-25(>100) \u00b5g/ml (Chen et al., 2004; Deng et al., 2012) Berbamine (N), bisbenzylisoquinoline alkaloids (19)", "cite_spans": [{"start": 61, "end": 80, "text": "(Chen et al., 2004;", "ref_id": "BIBREF113"}, {"start": 81, "end": 99, "text": "Deng et al., 2012)", "ref_id": "BIBREF12"}], "ref_spans": [], "section": "Scutellaria baicalensis"}, {"text": "HCoV-OC431.48 (>20) \u00b5M (Meng et al., 2013; Shen et al., 2019 ) HCoV-NL63 9.46 (>20) \u00b5M MERS-CoV 13.14 (>20) \u00b5M MHV-A59 10.91 (>20) \u00b5M Beta-sitosterol (N), steroid (20)", "cite_spans": [{"start": 23, "end": 42, "text": "(Meng et al., 2013;", "ref_id": "BIBREF61"}, {"start": 43, "end": 60, "text": "Shen et al., 2019", "ref_id": "BIBREF75"}], "ref_spans": [], "section": "Inhibits viral replication"}, {"text": "Inhibits enzymatic activity of virus (Lin et al., 2005) Hinokinin (N), lignoidC. obtuse var. Inhibits viral replication SARS-CoV >10 (>750) \u00b5M (Wen et al., 2007) Indigo (N), alkaloid ", "cite_spans": [{"start": 37, "end": 55, "text": "(Lin et al., 2005)", "ref_id": "BIBREF48"}, {"start": 143, "end": 161, "text": "(Wen et al., 2007)", "ref_id": "BIBREF94"}], "ref_spans": [], "section": "I. indigotica"}]}